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ABSTRACT
The extracellular capsule polysaccharide (CPS) of Vibrio vulnificus is a primary
virulence factor which allows survival o f the bacteria in the human host. To study the
genes involved in the production of the polysaccharide capsule, 23 mutants were
generated that lost their ability to produce CPS due to the insertion o f a mini-transposon
into the genome o f the encapsulated clinical strain V. vulnificus 1003 (O). The mutants
were examined by Southern blot analysis to ensure the transposon had inserted only
once in the chromosome. Exoenzymes, which are believed to contribute to the
virulence of the organism, produced by all 23 transposon mutants, the encapsulated
strain 1003 (O) and a spontaneously-derived translucent strain 1003 (T) were compared.
The transposon mutants produced the same exoenzymes as did 1003 (O), but the
translucent 1003 (T) varied in its ability to produce certain exoenzymes, suggesting that
the mechanism responsible for the loss o f capsule production in the environment may
effect exoenzyme production. Using a probe complimentary to the genomic region
disrupted by the transposon in one mutant, the putative capsule gene was located in the
parent strain 1003 (O) and then cloned and sequenced. Sequence analysis determined
that the gene disrupted by the transposon matched a nucleotide-sugar epimerase of
Vibrio cholerae 0139 with 75% and 85% identity at the nucleotide and amino acid
level, respectively. Numerous epimerases of various organisms were also recognized by
computer analysis to be highly similar to the putative epimerase o f V vulnificus. PCR
amplification and Southern blotting have shown that this epimerase is common to at
least ten strains o f V vulnificus that each express a serologically distinct CPS,
viii
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suggesting this gene product provides a precursor necessary for the production of CPS
independent of capsule type. Finally, the nonencapsulated mutant was capable of
reestablishing capsule formation upon introduction of the epimerase gene in trans,
indicating that the loss of CPS was due to the disruption o f the epimerase gene and not a
polar effect on downstream genes. It may therefore be concluded that the nucleotidesugar epimerase is essential for capsule production in Vibrio vulnificus.

ix

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

LITERATURE REVIEW
Before 1970, Vibrio isolates recovered from clinical specimens were put into
either one of two categories: 1) Vibrio cholerae, the well-known cause o f epidemic
cholera, or 2) non-agglutinable Vibrios, which consisted of a poorly defined group
known as “non-cholera Vibrios” (Blake et al., 1983). Since that time, the nonagglutinable group has been studied extensively and characterized due to the rise of
extraintestinal infections caused by the non-cholera Vibrios. Because toxigenic Vibrio
cholerae 01 seldom causes extraintestinal infections, the isolation o f Vibrios from
wound infections, ear infections, septicemia and the occasional case of meningitis
sparked an interest to characterize the non-cholera Vibrio species.
The bacterium known today as Vibrio vulnificus was classified in the genus
Beneckea in 1976, predicated on DNA hybridization studies, a G/C content o f 45-48%
and the presence of a single, sheathed polar flagella (Reichelt et al., 1976). Many
microbiologists, however, did not recognize the genus Beneckae and referred to B.
vulnifica as “L+ Vibrio” or “lactose-positive Vibrio” (Farmer, 1979). An early report
by Hollis et al. (1976) described a halophilic Vibrio that was similar to Vibrio
parahaemolyticus but could be distinguished by its ability to ferment lactose. Thirtyeight lactose-positive cultures were isolated from the blood, spinal fluid and wound
infections of patients between 1965 and 1976. It was then that Hollis suggested that
previous reports of Vibrio parahaemolyticus causing wound infections and septicemia
were most likely erroneous and were probably caused by the lactose positive Vibrio.
With the realization o f its clinical importance, it was suggested that the L+ Vibrio
1

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

2
should be given Vibrio species status (Hollis et al., 1976). In 1979, Farmer proposed
that Beneckae vulrtifica be changed to Vibrio vulnificus (Farmer, 1979) but the name
change was not formally accepted until abolishment of the genus Beneckae (Baumann et
a l, 1980). The nomenclatural problem was resolved by comparing the rRNA
homology and amino acid sequences o f glutamine synthetase, superoxide dismutase and
alkaline phosphatase o f Vibrio cholerae, with Beneckae species and Photobacterium
species. Because there were no unique differences to maintain separate genera, it was
concluded that the genus Beneckae would be abolished and its species transferred to the
genus Vibrio, which included V vulnificus.
Baumann et a/. (1980) also described V. vulnificus as an oxidase positive
organism which fermented glucose (with no gas production) and possessed a single
polar sheathed flagellum. The minimal salt concentration required for growth was 140
mM and its G/C content was determined to be 47.2%.
Conclusive evidence that Vibrio vulnificus was associated with serious
infections was presented in 1979 when Blake published the results o f a study with
isolates from blood, cerebrospinal fluid and wounds of 39 patients collected from 1964
to 1977. This was the first account o f an in-depth study showing that the “lactosepositive Vibrio ” can cause either o f two human illnesses. The first was described as an
overwhelming primary sepsis which began with chills, fever and then collapse with no
obvious focus of infection. In late stages o f infection, some patients developed necrotic
ulcers of the skin. With the exception o f one patient, all 24 patients had underlying
chronic illness which included liver disease, alcoholism, thalassemia or diabetes and
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each had ingested raw oysters within 36 hours prior to the onset of symptoms. Six
patients that developed hypotension died, with eleven deaths total, despite antibiotic
therapy. Both shock and disseminated intravascular coagulation (DIC) were believed to
be the cause of death. The second illness caused by the lactose-postive Vibrio started
with a superficial wound as a primary focus o f infection, that developed following a
crab bite or exposure of a pre-existing dermal wound to sea water. Dermal infection
began with swelling, erythema and pain near the wound. Fever and chills developed
and, in some cases, the wound became necrotic. In contrast to the patients who suffered
primary septicemia, only 1 of 15 patients had underlying hepatic disease. This patient
suffered from leukemia and was the only patient in this study to die o f the consequences
o f a wound infection. Blake also noted that most of these cases occurred in the warmer
months of May through October and that 90% o f the victims were men over 40 years of
age (Blake et al., 1979). This extensive study provided substantial evidence which
pointed to the clinical importance of Vibrio vulnificus.
From 1979 forward, numerous studies were done to document that several
Vibrio species may cause superficial and systemic infections in man. In the United
States, 11 Vibrio species have been reported to cause infectious disease. The most
recognizable agent is V cholerae 01, the etiological agent of epidemic cholera. V
cholerae non-Ols comprise a large group which cause diarrrheal disease and
extraintestinal infections, which may also include V fluvialis, V. hollisae, V. Jumissii,
V. mimicus and V parahaemolyticus. Among these, V parahaemolyticus is the most
frequent cause of infection. Finally, V. alginolyticus, V. damsela, V. metschnikovii and
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V. vulnificus cause extraintestinal infections and are rarely recovered from the stool
(Bonner et al., 1983; Morris and Black, 1985; Blake, 1983; Levine and Griffin, 1993;
Hlady and Klontz, 1996).
In 1989 a regional surveillence of the clinical and epidemiological characteristics
of Vibrio infections was conducted in the Gulf Coast states of Alabama, Florida,
Louisiana and Texas. This was the first year that each of these four states reported all
infections caused by Vibrio species to the Centers for Disease Control. Collectively,
121 infections were described and Louisiana reported the highest rate o f infection per
capita at 7 cases per one million persons. Seventy-one cases of gastrointestinal
infections (no deaths) were reported, and most were caused by either V.
parahaemolyticus or V. cholerae non-Ol. Twenty-nine wound infections, with 2
deaths, were reported and 8 were caused by V. vulnificus. Seven of the 14 cases o f
primary septicemia were caused by V. vulnificus. Sixty-seven percent o f patients with
septicemia had admitted to eating raw oysters shortly before the illness and each victim
had an underlying illness (Levine and Griffin, 1993).
A second and more comprehensive study was done over a 12 year period in
Florida and revealed that V. parahaemolyticus, V. cholerae non-Ol and V vulnificus
were the three most common Vibrio species associated with human illness. This study
showed that V parahaemolyticus and V. cholerae non-Ols were the most common
causes of gastroenteritis. V vulnificus was the most common cause of primary
septicemia, causing 75 (64%) of 118 total cases, with a 56% mortality rate. O f the
patients with primary septicemia, 83% reported eating raw oysters during the week prior
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to the onset of the illness and 87% suffered from liver disease or alcoholism (Hlady and
Klontz, 1996). This report confirmed a direct correlation between liver disease,
ingestion of raw shellfish and Vibrio vulnificus septicemia.
Subsequent surveys continue to confirm the triage of primary septicemia,
ingestion of raw oysters and Vibrio vulnificus. Since the underlying disease of the usual
victim is most often liver-associated, interest in the role that blood iron may play in the
etiology of infection resulted.

“Nutritional immunity” described by Weinberg (1974)

refers to the host’s ability to withhold iron from potential bacterial pathogens, thereby
depleting an element required to sustain growth. Because Gram negative organisms
require between 0.3-1.8 uM amounts of iron for growth, and the amount of free iron in
the human blood plasma o f a healthy individual is approximately 10‘12M, microbial
growth is inhibited. In fact, the defensive posture of a host upon systemic bacterial
invasion is to lower the amount of iron in the plasma by slowing the intestinal
absorption of iron and to increase sequestation o f iron in the liver (Weinberg, 1974).
Also, Interleukin 1, released by inflammatory cells during bacterial infection, is believed
to play a role in the lowering of serum iron by causing an increase in the production of
ferritin and its conversion to haemosiderin, which results in less transferrin-bound iron
(Wooldridge and Williams, 1993; Konijn and Hershko,l989). It follows that
immunocompromised individuals or persons with liver damage may not lower serum
iron levels in response to infection and the “nutritional immunity” defense is not
operational. This seems to be the scenario preceding Vibrio vulnificus infections in
which the usual victim is immunocompromised or suffers from alcoholism,
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hemochromatosis, diabetes, leukemia or thalassemia. These underlying chronic
conditions usually predict a possible lethal outcome.
Wright and colleagues in 1981 showed the importance o f available iron in the
pathogenesis of V vulnificus in what has become known as the “iron mouse” model
(Wright et al., 1981). The iron mouse model was implemented to mimic the septicemic
state o f a patient with high serum iron levels. In this study Wright et al. ran the 50%
minimal lethal dose (LD50) using 6-8 week old male mice challenged with various
dilutions of V vulnificus cells over a 72 hour period. These findings were compared to
the LDS0 values for mice whose serum iron level had been elevated by either
intraperitoneal injection with ferric ammonium citrate (FAC) (4 ug/g) or by carbon
tetrachloride (CC14) treatment. The hepatocellular necrosis caused by the CC14
treatment causes release o f iron stores from the liver to the serum (Reissmann et
al., 1954). Mice which received ferric ammonium citrate showed an LDS0 value o f 1.1
cells while mice not given FAC gave LD50 values of 6 x 106 cells. A similar
comparison was done on mice treated with CC14 where 2.1 x 103 cells caused deaths in 9
of 11 mice while no deaths occurred in the control mice. Treatment with CC14 was not
as dramatic as FAC but showed increased pathogenicity of V. vulnificus in the presence
of excess iron.
Because primary septicemias usually follow ingestion of raw oysters, V
vulnificus cells were administered by oral intubation into mice treated with CC14. The
LDS0in the control mouse group, which received V. vulnificus orally, was 1 x 109 cells.
Mice pre-treated with CC14 and then intubated with the same V vulnificus cells showed
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an LD50 of 103 cells, which also was the lowest Vibrio cell number tested. These
findings attest to the fact that elevated serum iron levels place the mice in jeopardy.
Wright et al. reported that iron was required for the growth o f V vulnificus in human
serum when they ran serum bacteriocidal assays. V vulnificus grew in rabbit serum,
which contains serum transferrin that is 60% iron-saturated, but not human serum,
which is only 30% saturated. They further proved their initial observation with the
addition of FAC at a concentration which permitted V vulnificus cells to propagate and
would not effect serum complement activity or opsonization (Fletcher, 1971). The
addition of excess iron reversed the bacteriocidal action o f the human serum.
Subsequently, Simpson and Oliver (1987) correlated virulence with the ability o f
V vulnificus to circumvent iron limitations. They showed that most strains tested could
pirate iron for growth in defferated medium from the fully saturated forms of both
ferritin and lactoferrin; however, neither apotransferrin nor 30% iron-saturated
transferrin supported growth. Only virulent strains, as determined by the LDS0assay,
could use fully saturated transferrin as an iron source for growth, while avirulent strains
were not able to obtain iron from the transferrin and did not survive.
It has been reported that virulent V vulnificus strains elaborated both
hydroxamate and phenolate (catechol)-type siderophores while an avirulent strain
produced the hydroxamate type only (Simpson and Oliver, 1983). Stelma et al. (1992)
also reported that avirulent strains do not produce phenolate siderophores and thus were
unable to utilize iron from fully saturated transferrin. The correlation o f phenolate
siderophore production and iron acquisition from transferrin was confirmed by Litwin et
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al. (1996) when they employed transposon mutagenesis to disrupt production of
phenolate siderophores. They showed that mutants which failed to utilize iron from
saturated transferrin gave an LDS0 of 2.6 x 106 (Litwin et al., 1996) which showed the
organism remained virulent as determined by Morris et al. (1987) who suggested that an
LDS0 of less than 107was characteristic of a virulent strain (Morris et al., 1987). Litwin
went on to show that the loss o f phenolate siderophore expression is directly responsible
for the inability to utilize transferrin bound iron, but this event does not render the
organism avirulent.
For individuals who suffer from hemachromatosis, serum transferrin is 100%
saturated, which produces a source o f free iron in the blood (Aruoma et al., 1988). In
agreement, Bullen et al. (1991) have shown that V vulnificus grows rapidly in blood
from patients with hemachromatosis but not in that of healthy individuals (Bullen et al.,
1991). Serum collected from alcoholics also supports rapid growth o f V. vulnificus
(Brennt et al., 1991), and these serum samples contain transferrin saturated at 98% . To
confirm that growth was due to highly saturated transferrin, Brennt et al. added
apotransferrin to the serum to render transferrin only 14% saturated. Apotransferrin
treated serum no longer supported the growth o f V. vulnificus, which attributes rapid
growth to highly saturated transferrin.
Another disease state that renders humans susceptible to V vulnificus infections
is thalassemia (Katz, 1988). Because these patients are severely anemic, it is not
obvious as to why this disorder results in high serum iron levels, but these patients
receive regular blood transfusions and parenteral iron as supplemental treatment. In
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addition, increased intestinal absorption occurs, which when coupled with treatments
often gives rise to iron overload (DeAlarcon et al., 1979).
Collectively, immunocompromised individuals with high serum iron levels are
more susceptible to infections by V. vulnificus than healthy individuals. Persons with
liver disease become infected at a rate 80 times greater than healthy persons. The
possibility of death is 200 times greater than that of a healthy individual who ingests
raw oysters (CDC, 1993). From 1988 to 1995, 302 V vulnificus infections have
occurred in the Gulf Coast states, with numbers increasing yearly. California, Florida
and Louisiana each require written notices at retail outlets (CDC, 1996) similar to the
label suggested by the CDC:
“Consumer Information-There is a risk associated with consuming raw oysters or any
raw animal protein. If you have chronic illness of the liver, stomach, or blood or have
immune disorders, you are at a greater risk o f serious illness from raw oysters and
should eat oysters fully cooked. If unsure o f your risk, consult a physician.” (CDC,
1993)
The realization that raw oyster consumption conveys Vibrio vulnificus infections
engendered many new approaches to isolate and enumerate Vibrio in oyster meat and
clinical specimens. Many bacteriological media selective for Vibrio species have been
developed. Because V vulnificus is an obligate halophile (Kelly, 1982), any isolation
media must obtain 0.5% to 3% NaCl to support growth. In addition, the organism is not
fastidious so grows well on a minimal media. The most widely used isolation medium is
thiosulfate-citrate-bile salts-sucrose (TCBS) agar (Kobayashu etal., 1963) where Vibrio
vulnificus colonies appear green (sucrose-negative), but unfortunately so do many
Vibrio species. Because TCBS supports the growth of heterologous bacterial genera,
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follow-up confirmatory testing is required. A media superior to TCBS for recovery has
been formulated. Colistin-Polymixin B-Cellobiose (CPC) agar (Massad and Oliver,
1987) takes advantage o f the resistance to polymixin B expressed by both V. vulnificus
and V cholerae and the fact that the remaining Vibrio species are susceptible to this
agent In addition, V vulnificus will ferment ceilobiose, which gives rise to yellow
colonies on the agar surface and distinguishes it from V. cholerae. CPC was shown to
be quite selective for recovery of V vulnificus from the environment when tested against
19 Vibrio species, the marine bacteria Pseudomonas, Flavobacterium, and
Photobacterium, none o f which grew on the medium (Oliver et al., 1992).
Detection of V vulnificus on CPC is presumptive evidence for the presence of
the organism. But identification must be confirmed, which can be done by a variety of
methods. Several methods were based on the cloning and sequencing of the cytolysinhemolysin gene of V. vulnificus (Wright et al., 1985; Yamamoto et a l, 1990), which
initially was the only sequence known to be unique to this organism. An early PCR
method amplified a 340 bp fragment in the hemolysin gene and detected as little as 72
pg o f DNA (Brauns et al., 1991) but was never tested with oyster homogenates. Wright
et al. (1993) developed a hemolysin-gene probe which they claimed could enumerate V.
vulnificus in oyster homogenates in less than 24 hours. Others have also utilized the
sequence of the hemolysin gene to construct probes to detect/identify V vulnificus
(Miceli et a l, 1993; Wright et a l, 1996) subsequent to primary isolation.
In addition to DNA probes, serology can also be utilized to identify V. vulnificus.
Tassin et al. (1983) used flagellar (H) specific antiserum to identify Vibrio species. A
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tube H-flocculation test can identify various Vibrio species with 98% accuracy within 2
hours following primary isolation (Tassin et a l, 1983). In addition, Simonson and
Siebeling utilized both poly and monoclonal species specific anti-flagellar antibody to
identify V vulnificus by a 2 minute coagglutination reaction which identified Vibrio
species in 99.3% agreement with bacteriological testing (Simonson and Siebeling,
1986). These researchers also coated latex beads with monoclonal H antibody which
agglutinated V vulnificus with similar precision (Simonson and Siebeling, 1987).
Various methods can be employed to detect and enumerate V. vulnificus with
good success, by either DNA probes or serology. They are useful tools to confirm the
presence of V vulnificus in both clinical and environmental samples following primary
isolation. But, to date, no test has been developed that can distinguish virulent from
avirulent strains of V vulnificus. The hemolysin gene is present in clinical and
environmental strains of V vulnificus, (Wright et al., 1993) and there is no correlation
between hemolysin production and virulence (Morris et a l, 1987; Oliver et al, 1986).
Wright et al. (1991) used transposon mutagenesis to disrupt expression of the
hemolysin gene in a virulent strain o f V. vulnificus. Both the parent and mutant strain
exhibited the same LDS0 values which suggested production of the extracellular
hemolysin did little to enhance the virulence of V vulnificus (Wright et al., 1991).
While recognition of species-specific H antigen through serology may be useful for
detection, both virulent and avirulent strains exhibit identical H antigens and this cannot
be utilized to distinguish virulent strains. Detection of virulent V. vulnificus cells in
oysters remains a goal for future researchers.
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A different approach was investigated by Tamplin et al. (1992) who attempted to
eradicate V vulnificus from oysters through a process known as depuration, which
involves submerging oysters in sterile water. While enteric pathogens such as
Salmonella and Escherichia can be purged from live oysters, Vibrio species cannot be
eliminated from the oyster meat. The study showed that V. vulnificus is a persistent
member of the microbial flora in the oyster and cannot be removed by depuration
(Tamplin and Capers,1992).
Kaspar and Tamplin (1993) examined the effect o f temperature and salinity on
the survival o f laboratory strains of V vulnificus in seawater. The numbers of V
vulnificus in the water column increased dramatically between the temperatures of 13°
and 22°C. Conversly, V vulnificus numbers dropped significantly when water
temperatures were dropped below 13°C or raised above 22°C. V. vulnificus could not be
recovered from water after 15 days incubation at 5°C. Optimal salinity for survival at
14°C occurred between 5 and 25 ppt (0.5 and 2.5% NaCl). These findings differed
from those reported by Kelly et al. (1982) who collected environmental samples over a
12 month period from Galveston Bay in the Gulf of Mexico. During the months of
December, January and February, the water temperatures were consistently below 20°C
and V vulnificus was rarely isolated. As temperature increased during the summer
months so did the numbers o f detectable V vulnificus. The greatest numbers were
recovered in September when water temperatures persisted at 25°C or greater for at least
4 months. Kaspar and Tamplin (1993) then set out to determine survival rates of
indigenous V vulnificus in oyster shellstock which were held submerged in salt water
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tanks. When oysters were stored at 0 ,2 and 4°C, the most probable numbers (MPN) o f
indigenous V. vulnificus cells decreased from 107 to 106 cells per 100 g oyster meat 4
days into storage, while after 10 days storage at 0°C less than 105 indigenous cells per
100 g remained and no cells could be recovered from the water. They concluded that V
vulnificus indigenous to the oyster were not susceptible to low temperature and seemed
to respond differently than laboratory strains. Because they noted a decrease in cell
numbers per 100 g oyster meat, they recommended low temperature storage for
postharvest oyster shellstock to control levels o f V. vulnificus.
The continued threat this organism presents to those with liver disease coupled
with the fact that the human infectious dose is unknown, results in the belief that even
low cell numbers of V. vulnificus in shellfish present a risk to the immunocompromised.
This is predicated on the fact that low cell numbers, as few as one cell, can cause death
in the iron mouse model (Wright et al., 1981), which mimics a person with high serum
iron levels. When encapsulated strains o f V vulnificus are tested in the LDS0 system, the
resultant LD50 varies from strain to strain in the number of organisms required to cause
death in mice. Do these numbers reflect a difference in virulence, differences in capsule
types, or the fact that they have been maintained in the laboratory setting for varying
periods of time? Different investigators report LDS0values for “virulent” strains o f V.
vulnificus, which range from 107 to 103 in untreated mice and from 10s to 1 cell for ironoverloaded mice (Stelma et a/., 1992; Morris et al., 1987; Wright etal., 1981). The LD50
studies indirectly suggest that all encapsulated strains o f V. vulnificus may not be
equally virulent.
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Because many extracellular substances are associated with virulence in Gram
negative pathogens, both clinical and environmental strains o f V vulnificus have been
tested for exoenzyme production. Oliver et al. (1986) developed assays for a variety of
exoenzymes. First, when virulence was assessed using the LDJ0 method, no differences
in LDS0 values were observed between clinical and environmental isolates. All strains
o f V. vulnificus lacked the ability to produce lecithinase and coagulase. Mucinase,
chondroitin sulfatase, hyaluronidase, DNase and (a) hemolysin were produced by all
strains examined. Oliver reported that proteolytic action on bovine serum albumin may
differentiate pathogenic from nonpathogenic strains because an avirulent V vulnificus
strain tested failed to hydrolyze BSA while all virulent strains produced the protease, a
finding which has not been verified. Elaboration of elastase, lipase and fibrinolysis
varied among strains tested (Oliver et a l, 1986). Morris et al. (1987) showed no
difference in protease or hemolysin production in virulent and avirulent strains, and
suggested a lack of correlation between exoenzyme elaboration and virulence. This
observation was in accordance with the LD50of a nonhemolytic mutant that was no
different from that of the parent strain which expressed a fully functional hemolysin
(Wright et al., 1991). It can be concluded that exoenzyme production is variable among
strains o f V vulnificus and a correlation between exoenzyme expression and virulence
has not been established.
In 1981, Kreger et al. described an “antiphagocytic surface antigen”, expressed
by virulent strains of V. vulnificus, which enabled isolates to resist the phagocytic efforts
o f human polymorphonuclear leukocytes (PMNL). Avirulent strains, on the other hand,
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were readily phagocytised. In addition, antibody specific for the outer surface of the
virulent cells enhanced phagocytosis of virulent strains (opsonization), but did not effect
that o f avirulent strains, which suggested that avirulent strains did not possess the
surface antigen. Adsorption of the antiserum with virulent cells (to remove antibody)
resulted in the loss of opsonization (Kreger et a l, 1981) and suggested that virulence
was due in part to the ability to resist phagocytosis. In 1984, Kreger et al. characterized
this “antiphagocytic surface antigen” further and showed that immunization of mice
with formalin-killed V vulnificus cells protected these mice from overt infection when
later challenged with virulent cells. In addition, electron microscopy and staining with
ruthenium red showed that virulent strains expressed an acidic polysaccharide on their
surface, while avirulent strains did not. Ruthenium red binds to acidic polysaccharides,
and exemplified a dense layer on the surface o f the virulent strains (Kreger et al., 1984)
which suggested that the “surface antigen” expressed by virulent strains was a
polysaccharide capsule. Subsequently, Amako et al. (1984) utilized both ruthenium red
and a rapid freezing method to visualize the extracellular polysaccharide and their
conclusion was the same as implied by Kreger et al.; the extracellular polysaccharide
was a capsule and cells which did not stain with ruthenium red were nonencapsulated.
They also suggested that absence of capsular polysaccharide may determine avirulence
(Amako et al., 1984).
Yoshida et al. (1985) described opaque colony types whose morphology on an
agar plate was directly related to capsule expression. Conversely, translucent variants
were shown to have no capsule. In addition, the opaque, encapsulated colonies were
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resistant to the bactericidal action of normal human serum and were also resistant to
phagocytosis (Kreger et al., 1984). Cells from opaque colonies gave LD50 values which
were 2 to 3 logs lower than translucent, nonencapsulated strains. The capacity to invade
and spread infection in subcutaneous tissue of guinea pigs was much greater for
encapsulated than for nonencapsulated strains after 1 hour and 4 hour periods. These
studies provided conclusive evidence that a correlation between capsule expression and
virulence exists. The random appearance of translucent colony types among opaque on
an agar plate is a common happening in the laboratory, but is not well understood.
Simpson et al. (1987) reported a correlation between the ability o f opaque cells
to utilize transferrin-bound iron and virulence. The LDS0 in iron overloaded mice was
lowered only by opaque and not translucent cells which suggested that the use of
transferrin-bound iron also aids in virulence. Simpson et al. (1987) also reported the
frequency of conversion from an opaque strain to a translucent was between 1% and
7%, while they never witnessed reversion o f translucent to opaque. These findings
conflicted with observations by Yoshida et al. (1985) and Wright et al. (1990) who
reported reversion at rates of 1.26 x 10"4 and 9.2 x 10'3, respectively. These two
accounts suggest that loss of capsule expression, while rare, is reversible, and not due to
deletion or recombination of genomic regions that result in the loss o f genetic material.
Collectively, various studies have provided evidence for the correlation between
encapsulation and virulence. The expression of a cell surface polysaccharide capsule
permits the cell to avoid phagocytosis and survive in normal human serum, while
nonencapsulated cells are readily phagocytised and succumb to the bacteriocidal action
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of serum. In addition, previous studies reveaied that avirulent strains do not produce a
phenolate siderophore, described earlier, and as a consequence fail to utilize transferrinbound iron (Simpson and Oliver, 1983; Stelma et al., 1992). Litwin showed that a
mutagenized virulent, encapsulated strain which lost phenolate siderophore production
was no longer able to use transferrin-bound iron, (Litwin et al., 1996) but did not lose
virulence as determined by the LD50 assay.
While encapsulation o f V vulnificus is now accepted to be the primary virulence
factor, the number of capsules expressed by this organism is unknown. Simonson and
Siebeling (1993) attempted to determine the minimal number of capsular serotypes
among clinical V vulnificus strains. Purified CPS prepared from three different clinical
strains was coupled to a protein carrier, to enhance immunogenicity of the
polysaccharide, and used to immunize rabbits. Staphylococcus aureus Cowan I cells
were armed with resulting anti-capsular antibodies (specific for each strain), and used
as a coagglutination reagent. Both encapsulated and nonencapsulated variants of
numerous V. vulnificus strains were tested for agglutination with each anti-capsular
reagent. O f 32 strains, only 3 encapsulated strains cross-reacted, suggesting the
existence of numerous capsule serotypes. Simonson et al. (1994) went on to further
identify at least 10 capsule serotypes.
Reddy et al. (1992) also attempted to distinguish CPS types in V vulnificus, but
used chemical composition to identify chemotypes. They purified and assessed the
chemical composition o f V vulnificus strains M06-24 and B062316 in two consecutive
studies (Reddy et al., 1992; Reddy et al., 1993). These two strains were used because
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anti-capsular antibodies o f M06-24 showed cross-reactivity with strain B062316,
indicating a similarity in CPS composition. The carbohydrate structures o f both
capsules were established using nuclear magnetic resonance spectroscopic analysis
(NMR). M06-24 CPS is composed o f a repeating unit that consists o f four sugars, 3
residues of 2-acetamido-2,6dideoxyhexopyranose in the a-gluco configuration
(quinovosamine) and 1 residue o f 2-acetamido hexouronate in the a-galacctopyranose
configuration (N-acetyl galactosamine) (Reddy et al., 1992). The CPS of B062316 also
contained four sugars per unit, 1 residue of quinovosamine, 1 residue of N-acetyl
galactosamine, 1 residue o f 2-acetamido-2,6-dideoxyhexopyranose in the a-galacto
configuration (N-acetyl fucose) and 1 residue of 2-acetamido-2,6-dideoxyhexopyranose
in the a-manno configuration (N-acetyl rhamnose) (Reddy et al., 1993). Each strain
contained both quinovosamine and N-acetyl galactosamine, suggesting that crossreactivity may have been due to these common residues. In addition to these two
chemotypes o f V. vulnificus, 13 additional chemotypes were identified based on
chemical composition and structure (Hayat et al., 1993). O f 19 environmental and
clinical strains tested, the most common sugars found in the CPS of V vulnificus were
fucosamine (37%), galactosamine (32%), quinovosamine (42%) and glucosamine
(32%).
Martin and Siebeling (1991) used monoclonal antibodies to establish 5 serotypes
o f V. vulnificus based on O-antigens associated with lipopolysaccharide (LPS). AntiLPS polyclonal antisera was used first but resulted in high levels of cross-reactivity.
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Instead, five anti-LPS monoclonal antibodies were used in the enzyme linked
immunosorbent assay (ELISA) to determine LPS serotypes.
In 1982, Tison et al. identified a second biogroup for V vulnificus strains
isolated from 6 locations in Japan that differed from current V. vulnificus isolates.
DNA-DNA hybridization studies showed that the new strains were V. vulnificus, but
differed by their inability to grow at 42°C, lack o f indole production and ornithine
decarboxylase activity, and each was isolated from a diseased eel. It was suggested that
current strains, such as the ATCC 27562 strain, should be classifed in biogroup 1, while
the new found strains isolated from diseased eels be placed in biogroup 2. Tison et al.
showed that while both biogroups 1 and 2 were pathogenic for mice, only biogroup 2
was pathogenic for eels. In addition, clinical and environmental strains o f biogroup 1
possess surface antigens that are heterologous, as shown by serology, but the surface
antigens of biogroup 2 are homolgous (Tison et al., 1982). Further studies have
continuously shown that biogroup 2 strains are isolated from diseased eels and are
serologically homolgous (Amaro et al., 1992; Biosca et al., 1996). Also, studies have
revealed that biogroup 2 isolates are virulent for eels in either the encapsulated or
nonencapsulated form, although the LDJ0 for nonencapsulated cells are 2-3 logs higher
(Biosca et al., 1993). In addition, the nonencapsulated biotype 2 isolates can utilize
transferrin-bound iron (Amaro et al., 1994). This is a remarkable difference compared
to phenotypic characteristics of the translucent strains of biogroup 1. It does, however,
indicate that capsule and iron acquisition are not directly related and may suggest that
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the loss of capsule production in biogroup 1 occurs through a different event than that of
a biogroup 2 strain.
In summary, V vulnificus is an opportunistic pathogen that is capable o f disease
through two routes of infection. Primary septicemia usually follows the ingestion o f
contaminated raw oysters by persons, usually middle-aged men, with high serum iron
levels. Wound infections usually occur in healthy individuals following exposure o f an
open wound to seawater or injury while cleaning shellfish. V. vulnificus causes greater
than 50% o f all extraintestinal infections caused by Vibrio species in the United States.
It is an obligate halophile, easily isolated from the marine environment and its
identification is easily confirmed through the use of serology or gene probes. It has
been established by the LD50 assay that the presence o f a polysaccharide capsule
(opaque strain) indicates the organism is virulent in mice. The iron mouse model has
shown that the excess unbound iron enhances the virulence o f encapsulated strains but
nonencapsulated strains are unaffected. The correlation between capsule expression and
iron acquisition is not understood and to further complicate the issue, translucent
strains of biogroup 2 are virulent for mice and can acquire iron from saturated
transferrin. Vibrio vulnificus isolates can be grouped by either CPS or LPS serotype or
chemotype. While it has been shown that within the species, numerous CPS and LPS
types are expressed, no correlation of virulence and specific types has been established.
In addition, the genes involved in CPS and LPS synthesis have not been identified.
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CHAPTER I. THE DISRUPTION OF GENES INVOLVED IN CAPSULE
SYNTHESIS OF VIBRIO VULNIFICUS B Y
TRANSPOSON MUTAGENESIS
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INTRODUCTION
In the laboratory, it has been noted on occasion that Vibrio vulnificus
encapsulated strains randomly become nonencapsulated. The resulting translucent,
nonencapsulated strains have been proven to be avirulent by serum sensitivity and LD50
testing (Wright et a l, 1990; Yoshida et al., 1985; Simpson etal., 1987). The
mechanism that determines this conversion is not understood. No extraneous
physiological condition, temperature or osmolarity has been shown to trigger the switch
from opaque to translucent. It is a random, spontaneous event which has been reported
at a rate o f 1-7% by Simpson et al. (1987), but has been observed at a much lower rate
in our laboratory and others (Yoshida et al., 1985).
In order to study this random event, the genes involved in capsule production
had to first be identified. Unsuccessful attempts at cloning the capsule gene locus of V.
vulnificus and expressing the polysaccharide capsule in an Escherichia coli cell implied
that either the capsule genes were scattered throughout the chromosome or a distant
regulatory region was somehow involved. Another option was to use a plasmid library
to complement the unknown mutation in a spontaneous, nonencapsulated strain of
Vibrio vulnificus, but this was also unsuccessful. Hence, attempts were made to disrupt
capsule production in order to obtain translucent strains. By disrupting capsule
production, the switching mechanism o f opaque to translucent may not be determined,
but the actual genes involved in capsule production may be identified.
Transposon mutagenesis, which has been used for previous studies in various
species of Vibrio, seemed to be the best method o f locating any genes involved, directly
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or indirectly, in the production o f polysaccharide capsule. The cholera toxin genes
(ctxA,ctxB), an outer membrane protein (ompV), and pilus expression (tcpA) (Taylor et
al, 1989) in V. cholerae, and phenolate siderophore production (yenB) (Litwin et al.,
1996) in V vulnificus have all been studied using TnphoA mutagenesis. In addition, the
phosphate regulation locus (pho) of V. parahaemolyticus (McCarter and Silverman,
1987), the luciferase (lux) genes of V harveyi (Martin et a l, 1989; Belas et a l, 1982)
and the capsule genes (rfb0l39) o f V cholerae 0139 (Comstock et a l, 1995, 1996) were
all isolated from the wild type strains using a probe designed from flanking
chromosomal regions of transposon mutants.
MATERIALS AND METHODS
Bacterial Strains and Plasmids. The encapsulated Vibrio vulnificus clinical strain
1003 (O) was used for transposon mutagenesis. The transposon vector pEIS, was
provided by Dr. Richard Cooper, Department of Veterinary Science, Louisiana State
University. The pEIS vector consists o f pGP704 (Miller and Mekalanos, 1988) in its
entirety with the mobilizable element, a mini-TnlOfkan derivative (Kleckner et a l,
1991), cloned into the EcoRI restriction enzyme site. Escherichia coli SMlOXpir
(Simon 1983, Miller 1988) was used to propagate pEIS for conjugation experiments.
Growth Conditions. V. vulnificus and E.coli cells were propagated in Heart Infusion
(HI) broth (Difco,Detroit, MI) supplemented with 2% NaCl for 18 hours at 37°C with
shaking at 200 rpm unless otherwise stated. Colistin (118 ug/ml), kanamycin (50
ug/ml) and ampicillin (50 ug/ml) were used when appropriate.
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Conjugation. A single colony was picked from the agar surface of plates containing
either V. vulnificus 1003 (O) or E.coli SMIOApir containing the pEIS vector and grown
in 3 ml HI broth. Kanamycin was added to the E.coli broth and both cultures were
incubated overnight at 37°C with rigorous shaking. One and a half ml of both V
vulnificus and E.coli was dispensed into microcentrifuge tubes and centrifuged at 16,000
x g for two minutes on a table-top microcentrifuge. Supernatant was discarded and the
cell pellet was resuspended in 1 ml of HI broth. Tubes were centrifuged at 16,000 x g
for 2 minutes and this wash step was repeated. Each cell pellet was resuspended in 15
ul and were then combined for a total o f 30 ul. One ul o f 100 mM IPTG was added to
the cell suspension to induce mini-Tn/0 transposition (Kleckner et al., 1991). The cell
suspension was then gently spotted onto a nitrocellulose square on the agar surface o f an
HI plate and was incubated at 30°C overnight. The filter containing the mixed culture
was transferred to a conical centrifuge tube containing 10 ml o f HI broth. The tube was
vortexed until no cell suspension was visible on the nitrocellulose filter and 100 ul was
spread onto HI plates supplemented with kanamycin and colistin. Plates were incubated
at 37°C overnight and colonies with a translucent phenotype were picked and frozen at
-85°C in HI broth containing 15% glycerol.
Probe Synthesis. The pEIS vector contains a kanamycin cassette which is not found in
the genome of Vibrio vulnificus. A digoxygenin (dig)-labeled probe specific for the
kanamycin gene was synthesized using the PCR DIG Probe Synthesis Kit (Boehringer
Mannheim, Indianapolis, IN). Primers were designed using Primer Designer Software
(1990,91 Scientific and Educational Software) specifically for the ends of the
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kanamycin gene to give a 980 bp PCR product Primers used were 5'
CAACAAAGCCACGTTGTGTCTCAAAATCTC 3' for the coding strand and 5'
TCAAGTCAGCGTAATGCYCTGCCAGTG 3' the noncoding strand. The pEIS
vector, isolated with the Perfect Prep Plasmid Isolation Kit (5 Prime 3 Prime, Inc.,
Boulder, CO), was used as the template for probe synthesis. Each 50 ul PCR mix, used
to synthesize dig-labeled probe, consisted of 2.5 mM MgCh, 10 ng template DNA, 5
mM o f each primer, 1 ul DMSO, 5 ul 10X buffer, 5 ul 10X dig-labeled nucleotide mix
and 2.6 units DNA polymerase ( Expand™-high fidelity). A total o f 30 cycles were
completed on a Perkin Elmer Cetus thermal cycler. The first ten cycles consisted o f
95°C for 10 seconds, 60°C for 30 seconds and 72°C for 2 minutes. Then 20 cycles at
95°C for 10 seconds, 60°C for 30 seconds and 72°C for 2 minutes with a 20 second
elongation starting at cycle 11. Twenty ul of the PCR mix was electrophoresed on a 2%
agarose gel to ensure amplification of the kanamycin gene.
Genomic DNA Isolation. The method used to isolate genomic DNA of all strains was
that of Chan and Goodwin (Chan and Goodwin, 1995). This protocol was modified for
nonencapsulated strains by omitting the addition of cetyltrimethylammonium bromide
(CTAB). Colonies were transferred from frozen stocks to tubes containing 3 ml HI
broth supplemented with kanamycin and were incubated overnight at 37°C with rigorous
shaking. Each 3 ml culture was divided in half into 1.5ml microcentrifuge tubes and
centrifuged at 16,000 x g for 2 minutes. The remaining pellet was washed twice with 1
ml of 1 M NaCI. Each pellet was resuspended in 520 ul TE (1 mM EDTA, 10 mM TrisHCI, pH 8.0), then 40 ul of pronase (20mg/ml) and 30 ul 10% SDS was added to each
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tube. Tubes were gently inverted to mix and incubated for 1 hour in a 56°C water bath.
One hundred ul 5 M NaCl was then added to each tube and incubated for 10 minutes at
65°C. One volume phenol/chloroform/isoamyl alcohol (25:24:1) was added and all
tubes were centrifuged for 15 minutes at 16,000 x g. Aqueous layers were transferred to
new microcentrifuge tubes using wide bore pipette tips and the extraction was repeated
using 500 ul phenol/chloroform/isoamyl alcohol. Isopropanol was added to the aqueous
layer at 0.6 volume and tubes were incubated at -85°C for 15 minutes to precipitate
DNA. Tubes were centrifuged for 5 minutes and pellets were washed once with 70%
ethanol. DNA pellets were allowed to dry overnight in a vaccuum dessicator, following
which 25 ul sterile water was added. All tubes were heated at 65°C for 15 minutes to
put DNA into solution and the two fractions were then combined into one tube.
Ribonuclease A (RNase A) was added to a final concentration o f 1 ug/ml and incubated
at 37°C for 30 minutes. Ammonium acetate (7.5 M) was added to each tube and DNA
was extracted with an equal volume of phenol/chloroform/isoamyl alcohol. Aqueous
layers were transferred to new tubes and 0.6 volume isopropanol was added. DNA was
precipitated at -85°C for 15 minutes, centrifuged, and each DNA pellet was washed once
with 70% ethanol. Pellets were dried in vaccuum dessicator overnight and then
resuspended in 30 ul sterile water.

Restriction Digests of Genomic DNA and Agarose Gel Electrophoresis. All DNA
preparations were resuspended in 30 ul sterile deionized HzO. To each of these tubes,
50 units of the appropriate restriction enzyme (NewEngland Biolabs Inc, Beverly, MA)
was added with 10X buffer and 100X bovine serum albumin (BSA) provided by the
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manufacturer, if required. Digests were incubated at 37°C overnight and then tubes
were heated to 65°C to denature the enzyme. The appropriate amount of 6X loading
buffer (0.25% bromophenol blue, 0.25% xylene cyanol, 40% sucrose in water) was
added to each tube and the entire contents were loaded into the wells of a 0.8% agarose
gel. The gel was electrophoresed for 24 hours at 20 volts at room temperature. Gels
were stained with ethidium bromide and visualized using a UV lamp on the EagleEye II
(Stratagene, LaJolla, CA) to ensure that restriction digestion did indeed take place.
Southern Blotting and dig-Chemiluminescent Detection. First, the gel of digested
chromosomal DNA was submerged in a 250 mM hydrochloric acid solution for 10
minutes with rocking, which allows a more efficient transfer of larger DNA fragments.
The gel was then rinsed with water and submerged in a denaturing solution (0.5 N
sodium hydroxide, 1.5 M sodium chloride) for 30 minutes to render the DNA single
stranded. The gel was then submerged in neutralization solution (1 M Trishydrochloride, 1.5 M sodium chloride, pH 8.0) for 30 minutes to neutralize the pH. The
DNA on the gel was transferred (or blotted) to a nitrocellulose filter by placing the gel
face down on a piece of Whatmann filter paper that has previously been soaked in 20X
SSC (3M sodium chloride, 0.3 M sodium citrate), a high salt solution. The
nitrocellulose filter was then placed on the back side of the gel. A two inch thick stack
of dry paper towels was then placed on top of the nitrocellulose filter and a small weight
on top to hold the set up in place. The salt solution was attracted to the dry paper towels
by capillary action and passed through the gel and nitrocellulose filter. The DNA was
carried through the gel and into the nitrocellulose filter, where it became trapped. The
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nitrocellulose filter displayed the DNA exactly as it was on the gel. Next, the DNA was
fixed onto the nitrocellulose filter by heating the filter at 80°C for 1 hour (Sambrook et
al., 1989).
The filter was then treated before it was exposed to the kanamycin probe. The
protocol o f the Genius 3 kit (Boehringer Mannheim) was followed and is briefly
reviewed here for explanation. The nitrocellulose was first submerged in 50 ml
prehybridization solution (5X SSC, 0.1% N-lauroylsarcosine, 0.2% sodium dodecyl
sulfate, and 1% skim milk in 0.1 M maleic acid and 0.15 M sodium chloride) in a
hybridization bag for two hours at 55°C. This prehybridization solution was a
“blocking” step which is necessary to prohibit the probe from binding non-specifically
to the filter. Next, the filter was submerged in hybridization solution, which contained
50 ml prehybridization solution with 20 ng/ml o f the dig-labeled kanamycin probe.
This was incubated at 55°C overnight in a water bath and allowed the probe to bind to
its complimentary strand of DNA on the filter. After a series of wash steps to eliminate
any unbound probe, the blot was developed by submerging the nitrocellulose filter in
blocking solution (1% skim milk, 0.1 M maleic acid, 0.15 M sodium chloride, pH 7.5)
for 30 minutes at room temperature. Then an antibody specific for the digoxigenin
(which was located on the probe itself) was added to the blocking solution. The
antibody was tagged with the enzyme alkaline phosphatase. After a series o f washing
steps to remove any unbound antibody (anti-digoxigenin) the substrates nitroblue
tetrazolium (NBT) and 5-bromo-4-chloro-3-indole-phosphate (BCIP) were added.
These substrates were recognized by the alkaline phosphatase enzyme, which removed a
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phosphate from the BCIP, and caused it to precipitate as a purple color on the filter.
The purple color indicated that the transposon, carrying the kanamycin gene, is located
in the genome on that particular fragment o f DNA.
RESULTS AND DISCUSSION
The approach used to disrupt capsule synthesis was to introduce a transposon
vector into an encapsulated strain of Vibrio vulnificus and isolate mutants which could
no longer produce a polysaccharide capsule. The mobilizable vector pEIS was chosen,
which is a combination of selected segments from two different bacterial plasmids.
The first segment is the plasmid pGP704 (Miller and Mekalanos, 1988; Timmis et al.,
1990), which will not replicate in V. vulnificus and also possesses the mobilization or
“mob” site necessary for conjugation. The second segment was derived from plasmid
pNK2859 (Kleckner et al., 1991). It encodes both the mobilizable transposon element
and the transposase gene. The mobilizable transposon region consists o f the kanamycin
resistance gene of Tn903 flanked on either side by the right insertion sequence of Tn/0
(IS10R). This plasmid was chosen for many reasons. First, the mobilizable element
was a “mini” transposon, meaning that the transposase is left behind on the vector while
the mobilizable transposon region inserts itself into the chromosomal DNA. Second,
the transposase gene itself had been mutated in two regions to allow a more random
insertion of the mobilizable cassette into the host chromosomal DNA. Third, the
transposase promoter is inducible by the addition o f IPTG, which allows for a controlled
and highly efficient transposition event. Once this transposon region was cloned into
pGP704, the end result, pEIS, was a specialized vector which allowed a random
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disruption o f genes using transposon mutagenesis in many Gram negative organism,
including Vibrio vulnificus.
From eight separate conjugation experiments, each yielding approximately 1,500
transformants, 23 translucent mutants resulted. The genomic DNA o f each mutant was
digested with seven restriction enzymes, Apal, £coRI, Kpnl, Sacl, SacH, Sail, zndXbal.
For each restriction enzyme, Southern blotting using the dig-labeled kanamycin probe
was employed to illustrate the fragment size into which the transposon had inserted, as
shown in Figure 1.1. Table 1.1 shows all 23 mutants grouped according to the size of
the insertion when digested with four of the seven restriction enzymes tested. Seven
classes of mutants resulted, suggesting that of all 23 mutants, only seven genetic regions
involved in capsule production were disrupted. In some cases, the same regions were
disrupted in mutants derived from separate experiments, ensuring the validity of the
mutant. Most mutants (48%) were of class #7, indicating this may be a “hot spot” for
transposon insertion.
The above data indicates that seven distinct genetic regions o f V vulnificus have
been disrupted. Taking into account the diverse restriction digestion fragment sizes of
the various classes o f mutants (Table 1.1), it may be assumed that at best, seven
different genes were rendered nonfunctional. Because the disruption o f these genes
resulted in the loss o f capsule production, it may be surmised that these genes were
essential to the expression o f the polysaccharide capsule. However, following
chromosomal digestion with a restriction enzyme such as Kpnl and Xbal, the fragments
of all seven classes o f mutants add up to greater than 70 kb of DNA, which suggests
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Figure 1.1 Southern blot of transposon mutant 54 which demonstrates the restriction
enzyme digested fragment sizes that contain the transposon insertion.
Hybridization of the dig-labeled kanamycin probe of chromosomal DNA of transposon
mutant 54 following digestion with restriction enzymes: Apal, lane 1; £coRI, lane 2;
Kpnl, lane 3; Sacl, lane 4; Sfldl, lane 5; Sail, lane 6; Xbal, lane 7.
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Table 1.1 Classification o f transposon mutants with corresponding fragment size of
insertion as determined by Southern hybridization with the dig-labeled kanamycin probe
(fragment sizes shown in kilobase units)
Class

Mutant

£coRI

Kpnl

Sad

Xbal

1

l1

8.3

4.5

2.3

12.7

2

4 3 \ 475

4.7

17

UD

14.2

3

443, 52s

15

15

11.7

8.8

4

454,4 6 s,
48s, 505

14.3

11.5

UD

8.3

5

51s, 53s

UD

12.8

UD

12.5

6

5T

14

10.5

9.8

5.6

8.5

13

12

14

7

342,3 8 2, 392,
402, 412,422,
546, 557, 56*,
58s, 59®

Superscript denotes the experiment from which each mutant was derived.
UD, undetermined (attempted but no clear results were obtained)
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that all o f the genes disrupted do not collectively form a single capsule gene locus.
Instead, these genes are most likely spread throughout the genome. While each of the
genes disrupted for each o f the seven classes o f mutants resulted in the loss of CPS
production, it is a possibility that some of these gene products are responsible for simple
sugar catabolism or have caused inactivation o f downstream genes by a polar event, and
their disruption indirectly resulted in the loss o f capsule production.
In the well established capsule gene locus o f E.coli group II capsules,
approximately 15 kb o f DNA is collectively responsible for capsule expression (Silver
et al., 1981). In E.coli K l, this 15 kb region is broken down into three regions. Region
1 is responsible for polymer translocation, is common to all E.coli group II capsules
and is comprised of six genes (Pazzani et al., 1993). Region 2 is serotype specific and
responsible for nucleotide synthesis, sugar transferases and polymerization, is 5.8 kb in
length and encodes six genes (Silver, 1994). Region 3 is believed to be involved in
post-polymerization translocation, is also conserved in organisms expressing group II
capsules and encodes only two genes (Pavelka et al., 1991). Collectively, this 15 kb
region contains 14 genes which are essential for capsule synthesis. In Haemophilus
influenzae type b, it was shown that two 18 kb tandem repeats separated by a 1.3 kb
region were sufficient to express the capsule (Hoiseth et al., 1986). A genomic region
of 23 kb in Klebsiella pneumoniae is responsible for capsule synthesis (Arakawa et al.,
1991). With the capsule loci of these three organisms between 15 and 23 kb, those
seven genes disrupted in the V. vulnificus transposon mutants most likely represent less
than half o f the genes responsible for capsule synthesis.
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INTRODUCTION
Vibrio vulnificus, the most invasive of the Vibrios, causes disease by two routes
of infection. It is capable of crossing the intestinal barrier following the ingestion of
raw seafood to result in a primary septicemia and may also cause massive tissue
destruction and necrosis o f open wounds following exposure to the marine environment
(Blake et al., 1979, Hollis et al., 1976). The ability of V vulnificus to persist and cause
disease is dependent upon the expression of a polysaccharide capsule, (Yoshida et al.,
1985) as discussed earlier. In addition, it has also been shown that the ability of the
organism to acquire iron from saturated transferrin allows the organism to thrive
(Simpson and Oliver, 1987). But these two virulence factors alone do not account for
invasiveness. Furthermore, various exoenzyme activities have been associated with the
pathogenicity of the organism (Kothary and Kreger, 1985; Kreger et al., 1981; Testa et
al., 1984; Smith and Merkel, 1982; Oliver etal., 1986).
The bacterial pathogens Clostridium perjringens, Streptococcus pyogenes and
Pseudomonas aeruginosa produce an array of exoenzymes that promote invasiveness
and virulence by facilitating the spread of the organism and destruction of neighboring
tissue (Pelczar and Reid, 1958; Clark et al., 1984). The tissue destruction caused by
each o f these organisms is mimicked by V vulnificus, which suggests that V vulnificus
may also utilize exoenzymes to cause tissue pathology. Even though two diverse routes
of infection occur, it seems likely that V vulnificus may require exoenzymes to invade
and disseminate from the portal of entry.
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It has been shown that strains of V. vulnificus which express a polysaccharide
capsule are virulent in mice, while nonencapsulated strains are avirulent (Yoshida et al.,
1985; Wright et al., 1990). The spontaneous loss of capsule expression, which gives
rise to the translucent colony phenotype, is not understood, but is known to result in an
avirulent strain. Also, what is not understood, is whether other virulence factors are
lost in addition to capsule expression, upon spontaneous conversion from an opaque to a
translucent variant. Is the loss of capsule alone directly responsible for the subsequent
loss of virulence, or are other factors, such as expression of exoenzymes also lost during
this event?
To address these concerns, the 23 nonencapsulated transposon mutants described
in Chapter 1, a nonencapsulated spontaneous variant 1003 (T) and the wild type
encapsulated strain 1003 (O) were each assayed for various exoenzyme activity which
have been reported to enhance virulence in other bacterial pathogens. In addition, 1003
(O), 1003 (T) and two transposon mutants were tested for virulence in the iron-mouse
LDS0 model (Simpson et al., 1987).
MATERIALS AND METHODS

Bacterial Strains and Growth Conditions. The encapsulated strain Vibrio vulnificus
1003 (O), the spontaneous nonencapsulated strain 1003 (T) and 23 nonencapsulated
transposon mutants (derived from 1003 (O)) described in Chapter 1, were used in this
study. V vulnificus strains were grown in Heart Infusion (HI) broth (Difco)
supplemented with 2% NaCl and then transferred to the appropriate medium for each
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assay system. The HI cultures were incubated for 16 to 18 hours (overnight) at 37°C
unless otherwise stated.
Exoenzyme Detection Assays. The expression o f fibrinolysis activity was tested by the
addition o f filter sterilized human fibrinogen (Sigma, St. Louis, MO) at 2.8 mg/ml to
Heart Infusion Agar (Difco), supplemented with 2% NaCI, previously allowed to cool to
51°C (Janda and Bottone, 1981). The agar plate was divided into quadrants and
overnight HI broth cultures were tested by placement o f 10 ul of each isolate onto the
agar surface. Plates were incubated overnight at 37°C. A positive test was noted by the
presence of a clear zone surrounding the spotted colony on the agar surface and zone
sizes were measured.
To detect mucinase activity the following reagents were prepared. One hundred
ml of a 2% solution of porcine stomach mucin (type II, Sigma, St. Louis, MO) in water
was prepared. Next, 100 ml of a 2X concentration o f HI agar (Difco) supplemented
with 2% sodium chloride was prepared. The 2% mucin solution and HI agar were
autoclaved separately, allowed to cool to 51°C, combined, and poured into petri dishes
(Oliver et al., 1986). Ten ul o f each test isolate was spotted onto each quadrant o f the
mucin- HI agar. The plates were incubated overnight at 37°C and the presence of a clear
zone surrounding the colony indicated mucinase activity.
The expression of collagenase activity was assayed in the following manner.
Hide Powder Azure (Sigma, St. Louis, MO) was the substrate used to detect enzymatic
activity. HI agar was prepared and the following items were added: 0.05 M Tris (pH
8.0), 1 mM ZnCL, 10 mM CaCl, 2% agar and a 1% solution o f Hide Powder Azure
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(HPA) was added to give a final concentration of 0.2% (Holder, 1983). Each plate was
divided into quadrants into which wells were punched in the agar. A 100 ul aliquot of
supernatant fluid collected from HI broth cultures was then added to each well. Plates
were incubated overnight and a positive test was recognized by disappearance of the
blue (azure) color surrounding each well.
The elastase assay required a 2 ml culture of each V. vulnificus isolate tested.
Each isolate was grown for 16 hours in HI broth supplemented with 2% NaCl, 10"4M
ZnCU and I O'3 M CaCl2. Following 16 hours incubation, 20 mg elastin-Congo Red
powder (Sigma, St. Louis, MO) was added to each broth culture and incubated for 1
hour at 37°C. Cells were sedimented by centrifugation and the supernatant fluid was
assayed on a spectrophotometer at 488 nm. A reading of 0.1 was considered positive
(Oliver et al., 1986).
Bovine serum albumin (BSA) was the substrate used to detect protease activity
(Oliver et al., 1986). A 2% solution o f filter sterilized BSA was added to tempered
(51°C) double-strength HI agar supplemented with 2% NaCl. The BSA-HI agar was
divided into quadrants, and 10 ul aliquots o f each test culture were dropped onto the
agar surface. The plates were incubated overnight and were developed by the addition
o f 12.5% HgCI, in 1 M HC1. After 2 minutes the plates were examined for the
presence of clear zones which indicated a positive test for protease production.
Gelatinase activity was detected in nutrient gelatin broth (Difco) supplemented
with 2% NaCl and 1.5% agar (Norqvist et al., 1990). Agar plates were divided into
quadrants and 10 ul o f a broth culture were dotted onto the agar surface. Plates were
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incubated at 25°C for 48 hours. The addition of 12.5% HgCl, in 1 M HC1 onto the agar
surface was used to coagulate nondigested gelatin and a clear zone indicated gelatinase
activity.
The presence o f proteolytic activity was also tested by the addition of skim milk
to HI agar, which detects caseinase activity (Norqvist et al., 1990). A 2% solution of
skim milk and double-strength HI agar with 2% NaCl were prepared simultaneously.
The HI and milk were autoclaved, tempered to 51°C and mixed, resulting in 1% skim
milk. Ten ul aliquots of each HI broth culture were dotted onto the agar surface and the
plates were incubated overnight. A clear zone surrounding the spotted inoculum
indicated a positive test
Deoxyribonuclease (DNase) activity was detected by spotting each test organism
onto Methyl Green DNase agar (Difco) supplemented with 2% NaCl. Ten ul aliquots of
broth cultures were dropped onto the agar surface and were incubated at 37°C for 48
hours. DNase activity was noted by the appearance of a clear zone around each colony
(Oliver et al., 1986).
To test for lipase activity, isolates were inoculated onto HI agar supplemented
with the substrate Tween 80 (polyoxyethylene sorbitan mono-oleate) at a final
concentration o f 1% (Oliver et al., 1986). A positive test was indicated by a hazy zone
surrounding each colony.
Hyaluronidase activity was assessed by adding filter sterilized umbilical sodium
hyaluronidate (Sigma, St. Louis, MO) to tempered HI agar to give a final concentration
o f 400 ug/ml. Each plate was divided into quadrants, onto each of which 10 ul of cells

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

40
were spotted. After overnight incubation, 2 N acetic acid was applied to the surface.
Hyaluronidase activity was detected by a clear zone around each colony (Smith and
Willett, 1968).
Chondroitinase activity was detected by a method similar to that used to detect
hyaluronidase. Filter sterilized bovine nasal chondroitin sulfate (Sigma, St. Louis, MO)
was added to tempered HI agar to give a final concentration o f400 ug/ml. Assay plates
were divided and 10 ul aliquots of each test cell suspension were spotted onto each
quadrant. After overnight incubation, 2 N acetic acid was added. Clearing around test
colonies indicated a positive result (Smith and Willett, 1968).
Hemolysin production was ascertained by spotting 10 ul aliquots o f cells onto HI
agar supplemented with 5% sheep red blood cells. A P-hemolytic zone around a colony
suggested hemolysis or complete lysis o f the cells, while a green-brown zone
surrounding a colony suggested partial hemolysis.
50% Lethal Dose (LDg,). A colony was selected from an HI agar plate, transferred to a
10 ml tube of HI broth and incubated at 37°C with shaking until an OD6I0 o f 0.15 to 0.2
percent absorbance was obtained. One ml was removed, centrifuged in a microfuge
tube and the supernatant fluid was discarded. The cell pellet was suspended in 1 ml
phosphate buffered saline (PBS) and added to a centrifuge tube containing 9 ml PBS (a
10'1dilution of the cells). Cells were vortexed to give a uniform suspension and 1 ml
was removed and transferred to a second tube which contained 9 ml PBS (a 10*2dilution
of cells). This 10-fold serial dilution scheme was repeated through six additional tubes,
ending with a 10*®dilution. Dilutions 10*' and 10‘3 were discarded at this point. Two

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

and a half ml of each cell dilution (10'2,1 O'4,10‘5,10"6,10'7 and 10"*) were drawn into
each of six 3 ml syringes with 26 3/4 gauge needles. To estimate cell numbers at each
dilution, an HI plate was spotted with 10 ul o f each dilution in triplicate. Plates were
incubated at 37°C overnight and colonies were counted.
A solution o f ferric ammonium citrate (FAC) at a concentration o f 248 mg/ml in
PBS was prepared and filter sterilized. Seven tuberculin syringes fitted with 26 3/4
gauge needles were each filled with 1 ml FAC solution.
Five (six week old male) mice were injected intraperitoneally with 0.5 ml of
cells of each dilution and 0.2 ml of FAC in succession (Simpson et ah, 1987). Mice in
each group were injected with the same syringe, utilizing the entire 2.5 ml cell
suspension and 1 ml of FAC in each syringe. For each Vibrio strain tested, a total of
thirty mice were injected and monitored for 48 hours, and lethality counts were recorded
at 24 and 48 hours, at which time dead mice were removed from the cage. The method
of calculating the LDS0 by Reed and Muench (1938) was employed in this study and is
reviewed in Appendix A.
RESULTS AND DISCUSSION
In assessing virulence, the capacity o f the organism to survive and thrive in the
tissue environment o f the host is obviously o f utmost importance to the pathogen. The
polysaccharide capsule o f V vulnificus has been labeled as a primary virulence factor
simply because it enables the organism to escape the defense mechanisms and tactics
employed by the human host, permitting the organism to survive. Secondary virulence
factors have been described which may assist V. vulnificus to spread in the tissue.
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Elaboration o f an array o f exoenzymes (Oliver et al., 1986; Kreger and Lockwood,
1981; Rodrigues et al., 1992; Morris et al., 1987; Gray and Kreger, 1985) are believed
to contribute to pathogenicity which enable this organism to cause tissue inflammation.
Collectively, these exoenzymes can destroy connective tissue, lyse fibrin clots, dissolve
cell membranes, and move through mucus barriers. Some exoenzymes produced by V.
vulnificus, such as elastase and hemolysin, have been shown to be toxic when injected
into mice (Gray and Kreger, 1985; Kothary and Kreger, 1987). Conversely, disruption
of the hemolysin gene in virulent strains o f V vulnificus does not result in a lower LDS0,
which suggests that hemolysin is not essential for virulence (Wright and Morris, 1991).
To date, exoenzymes have been described as secondary virulence factors and the exact
role they play in virulence remains ambiguous.
The fact that encapsulated strains o f V. vulnificus are virulent and
nonencapsulated strains are not has been established. Both environmental and clinical
strains have been compared in their ability to produce exoenzymes, and no measurable
differences have been found (Oliver et al., 1986; Rodrigues et al., 1992), but no
comparison of exoenzyme production has been made between opaque and translucent
strains. The generation of the 23 nonencapsulated transposon mutants, where allegedly
only capsule synthesis had been disrupted, presented the opportunity to study the effect
o f the loss of capsule upon the expression o f various exoenzymes. The correlation
between capsule expression and exoenzyme production has not been previously
examined. If the secretion o f any exoenzyme is dependent upon the integrity of the cell
membrane o f an encapsulated organism, or an event that occurs during the translocation
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of the polymerized capsule, then a divergence in exoenzyme production may be
observed between encapsulated and nonencapsulated strains. Strain 1003 (T) also had
to be considered, whose mechanism of conversion from opaque to translucent is
unknown. If any genetic rearrangements or deletions occur in this conversion, there
may be an effect or even a loss o f the secondary virulence factors as well, resulting in an
avirulent strain because o f a combination of events, perhaps not just the loss of capsule
expression.
Table 2.1 identifies each o f the exoenzymes which V. vulnificus has been
reported to elaborate. V vulnificus 1003 (O), 1003 (T) and each of the 23 transposon
mutants were compared. None of the strains tested produced hyaluronidase, chondroitin
sulfatase or elastase. Hyaluronidase, also known as the “spreading factor”, enhances
tissue penetration by hydrolyzing hyaluronic acid, a component of the extracellular
matrix, the ground substance o f many tissues (Smith and Conant, 1960). Chondroitin
sulfate is another constituent of the matrix which helps form the proteoglycans of
connective tissue, and is hydrolyzed by chondroitin sulfatase (Stryer, 1988). Elastase
also degrades connective tissue, specifically the elastin fibers found in blood vessel
walls and ligaments (Stryer, 1988). Collectively, these three exoenzymes are capable of
tissue necrosis, but they are not always detectable in virulent V vulnificus strains.
While the production of both elastase and chondroitin sulfatase varies from strain to
strain (Rodrigues et al., 1992; Biosca and Amaro, 1996; Oliver et al., 1986), Oliver et
al. (1986) report that every environmental and clinical strain they tested produced
hyaluronidase. Investigators have shown that strains which do not
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Table 2.1. Comparison o f exoenzyme activities for the encapsulated strain V. vulnificus
1003 (O), a nonencapsulated 1003 (T) and 23 nonencapsulated transposon mutants
derived from 1003 (O).
Exoenzyme Activity
Examined

V. vulnificus
1003(O)

V. vulnificus
1003 (T)

Transposon
Mutants

General protease

+a

0C

fibrinolysis

+

db

gelatinase

+

d

-F

caseinase

+

d

+

mucinase

+

+

+

collagenase

+

+

+

hemolysin

+d

+d

+d

DNase

+

+

+

lipase

+

+

+

hyaluronidase

0

0

0

chondroitin sulfatase

0

0

0

elastase

0

0

0

a discernible detection o f exoenzyme activity
b decreased production (compared to the wild-type encapsulated strain)
c no detection of exoenzyme activity
d P-hemolysis
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produce elastase or chondroitin sulfatase were fully virulent (Oliver et al., 1986; Biosca
and Amaro, 1996), suggesting these two exoenzymes are not essential for virulence.
Mucinase, collagenase, P-hemolysin, lipase and DNase activities were detected
in all strains tested. Mucinase is believed to be critical for colonization o f Vibrio on the
mucosal lining of the gut (Oliver et al., 1986). This enzyme liquifies mucin and
enables the organism to penetrate this barrier to reach the gut enterocyte surface.
Reports of mucinase production by V. vulnificus are conflicting. Oliver et al. (1986)
reported ail strains they tested produced mucinase, while Biosca and Amaro (1996)
reported none of strains they tested produced the enzyme. Each of the 25 isolates tested
in this study (Table 2.1) elaborated mucinase activity, however, the role mucinase plays
in virulence is unknown. Collagenase supports the spread of infection by hydrolyzing
the collagen fibers in connective tissue in muscle, bone and cartilage (Pelczar and Reid,
1958). Smith et al. (1982) reported collagenolytic activity of V vulnificus and
suggested the enzyme was a major contributor to virulence. Beta-hemolysin was
produced by ail strains tested and produced complete lysis of red blood cells on agar
plates. For gastroenteritis produced by Vibrio parahaemolyticus, only hemolytic strains
were believed virulent, and for this Vibrio pathogen hemolysin is thought to be an
essential virulence factor (West and Colwell, 1984). This does not appear to be the case
for V vulnificus because when expression o f the hemolysin gene is disrupted and loss of
hemolytic activity results, there is no loss o f virulence (Wright and Morris, 1991).
Hemolysin production by V vulnificus is not a constant. There are reports of
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variable production, and reports that both a and P-hemolysins are produced (Oliver et
al., 1986; Biosca etal., 1996; Rodrigues et al., 1992; Amaro et al., 1992).
Lipase was also produced by each strain tested. Lipases may exhibit a lipolytic
activity which leads to dissolution o f cell membranes and is accomplished by splitting
fats into di- or monosaccharides and fatty acids (Crueger and Crueger, 1984). Vibrio
vulnificus lipase was described by Testa et al. (1984) and was detected in supernatant
fluids of virulent organisms at higher levels than for avirulent strains. Subsequently,
virulent strains of V. vulnificus have been identified which do not secrete detectable
levels o f lipolytic activity (Oliver et al., 1986; Biosca and Amaro, 1996; Amaro et al.,
1992), which implies that the enzyme is not essential for virulence.
Gelatinase, fibrinolysin and protease activities were each produced by 1003 (O)
and each of the 23 transposon mutants, and in varying levels by 1003 (T). Proteolytic
activity was measured two ways, using either casein or bovine serum albumin (BSA) as
the substrate. V vulnificus 1003 (O) and each of the transposon mutants produced
pro teases which hydrolyzed both casein and BSA, while 1003 (T) produced caseinase
only, and did not hydrolyze BSA, a finding which suggested that these two substrates
can be distinguished and tire most likely hydrolyzed by two separate proteases. Previous
investigators which studied proteolytic activity utilized casein as the substrate, and
showed all V. vulnificus strains tested possessed caseinase activity (Biosca et al., 1996;
Amaro et al., 1992; Morris et al., 1987). A decrease in caseinase production by 1003
(T) was observed (Table 2.1) when compared to that of 1003 (O) and each of the
transposon mutants, as measured by by the zone of clearing around each colony (Figure
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2.1). This decreased protease production by 1003 (T) may not result in a loss of
virulence, since Morris et al. (1987) reported no correlation between decreased
caseinase production and virulence. These findings suggest that this enzyme does not
play a large role in virulence. When BSA was employed as the substrate, no proteolytic
activity was detected for 1003 (T). Vibrio vulnificus 1003 (O) and each transposon
mutant produced detectable clear zones surrounding each test colony. Proteolytic
activity specific for BSA has been proposed by Oliver et al. (1986) to be a candidate for
identification o f virulent strains since only virulent strains tested produced this enzyme,
while avirulent strains did not. V. vulnificus 1003 (T) did not express BSA-specific
protease activity (Table 2.1), which supports Oliver’s contention, which may be of
importance if a correlation between virulence and protease activity can be confirmed.
However, when spontaneously derived translucent strains from ten different capsular
serotypes of V vulnificus were tested, only the 1003 (T) strain was negative for BSAspecific protease activity. This implied that the hypothesized correlation between
virulence and protease production was seemingly coincidental.
Fibrinolytic activity was produced at higher levels by 1003 (O) and each of the
23 mutants than by 1003 (T) (Figure 2.1). The clear zone around each colony was
measured. The diameter of the zones surrounding 1003 (O) and each mutant was 18
mm or greater, while the diameter surrounding 1003 (T) did not exceed 11 mm.
Fibrinolysis causes dissolution o f fibrin clots, which can impede the healing processes
and promote the spread of infection (Crueger and Crueger, 1984). Gelatinase was also
seemingly produced at lower levels by 1003 (T). Gelatin, a supporting matrix in bones
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Figure 2.1. Comparison o f caseinase and fibrinolysis exoenzyme production of 1003
(O), 1003 (T) and 3 nonencapsulated transposon mutants.
Plate assays for caseinase and fibrinolysis activity shown in panels A and B,
respectively. A discernible difference in caseinase and fibrinolysin activity for Vibrio
vulnificus 1003 (T) can be seen when compared to the larger zones o f V. vulnificus 1003
(O) and 3 transposon mutants.
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and tissues, is hydrolyzed by gelatinase activity. The impact gelatinase activity imparts
to virulence has not been determined, but all strains of V vulnificus tested to date
produce this enzyme (Biosca and Amaro, 1996; Amaro et al., 1992).
These results indicate there is no correlation between loss o f capsule production
and exoenzyme activity, and suggest that each o f the 23 transposon mutants differed
from 1003 (O) only in their ability to synthesize and exhibit a polysaccharide capsule.
Each mutant exhibited the same secondary virulence factors as the encapsulated 1003
(O), and absence of capsule did not effect exoenzyme production in any discernible
way. However, the spontaneously derived 1003 (T) exhibited decreased fibrinolysis,
caseinase and gelatinase activity.
Virulence for encapsulated or nonencapsulated V. vulnificus strains is defined in
mouse lethality studies by a 50% minimal lethal dose (LDJ0) assay. To assess the
impact capsular carbohydrate brings to virulence in relation to the secondary virulence
factors, an LD50 study was done on 1003 (O), 1003 (T) and the transposon mutants.
Since V vulnificus 1003 (O) is highly encapsulated and elaborates an array o f secondary
virulence factors, it was expected to give a low LDS0. Each transposon mutant
elaborated the same secondary virulence factors o f the parent encapsulated
strain 1003 (O), but lacked a capsule. Strain 1003 (T) also lacked a capsule but its
exoenzyme production differed slightly from the other V vulnificus strains.
Using the iron mouse model, the LDS0 for 1003 (O), 1003 (T) and transposon
mutants 47 and 54 were determined by the method of Reed and Muench (1938),
reviewed in Appendix A. The encapsulated V vulnificus 1003 (O), gave an LDS0 o f
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0.87 or 1 cell. Mice injected with 125 cells or greater (dilutions 10'2, 10“*and 10"5) died
within 24 hours (Table 2.2) and four o f five mice challenged with 12.5 cells died. There
were no additional mortalities after 48 hours. When injected with 1.25 cells, three of
five mice died within 24 hours, and no deaths followed. One o f four mice challenged
with 0.125 cells (at 10‘8 dilution) died in the 48 hour period. The calculated LDS0 or
50% lethal dose for 1003 (O) was 0.87 or 1 cell (Table 2.3).
The LD50 for V vulnificus 1003 (T) could not be determined because there were
no mortalities among the 30 mice over the 48 hour period, which were challenged with
a maximum o f 6.5 x 107cells. This strain is therefore defined as avirulent and the 50%
lethal dose is greater than 6.5 x 107 cells (Table 2.3)
Two transposon mutants, 47 and 54, were shown to be avirulent in the LDS0
assay. Neither mutant killed mice, even when challenged with 2.5 x 107 and 2.4 x 107
cells, respectively. The number of cells injected into each group o f five mice for each
dilution of cells is also shown on Table 2.2.
In summary, V vulnificus 1003 (O) differed from each transposon mutant in one
recognizable manner, it expressed a polysaccharide capsule. Absence o f capsule
expression in the transposon mutants resulted in the complete loss o f virulence, as
shown by the LDS0 assay. Among the spontaneously derived nonencapsulated strain of
1003 (T) and transposon mutants, the effect that loss of exoenzyme production exerts on
virulence cannot be estimated because each nonencapsulated strain tested was found to
be avirulent. The implication; the polysaccharide capsule is a primary virulence factor,
while exoenzymes may facilitate the infection, as secondary virulence factors.
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Table 2.2. Lethal dose 50% (LD50) values for the encapsulated 1003 (O),
nonencapsulated 1003 (T) and nonencapsulated transposon mutants 47 and 54.
V vulnificus
Cell
Strain Tested Dilution*
1003 (O)

1003 (T)

Mutant #47

Viable
CFUb

Mice0
Alive Dead

Totald
Alive Dead

Percent
Mortality

lO'2

1.25 x 10s

0

5

0

23

100

10“*

1.25 x 103

0

5

0

18

100

10's

1.25 xlO 2

0

5

0

13

100

io-6

1.25 x 10'

1

4

1

8

89

lO'7

1.25 x 10°

2

3

3

4

57

IO'8

1.25 x IO'1

3

1

6

1

14°

IO'2

6.5 x 107

5

0

5

0

0

io-4

6.5 x 10s

5

0

10

0

0

io-5

6.5 x 104

5

0

15

0

0

io-6

6.5 x 103

5

0

20

0

0

io-7

6.5 x 102

5

0

25

0

0

IO'8

6.5 x 10'

5

0

30

0

0

IO'2

2.4 x 107

5

0

5

0

0

IO-*

2.4 x 10s

5

0

10

0

0

IO'5

2.4 x 104

5

0

15

0

0

io-6

2.4 x 103

5

0

20

0

0

io-7

2.4 x 102

5

0

25

0

0

IO'8

2.4 x 101

5

0

30

0

0
(table con’d.)
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2.55 x 107

5

0

5

0

0

10-4

2.55 x 10s

5

0

10

0

0

10-5

2.55 x 104

5

0

15

0

0

10-6

2.55 x 103

5

0

20

0

0

10-7

2.55 x 102

5

0

25

0

0

00
o

a
b
c
d
c

10*2

2.55 x 10'

5

0

30

0

0

dilution of original cellular suspension used to inject 5 mice in each group
actual number of cells per 0.5 ml aliquot injected into each mouse
viability/mortality counts of mice 48 hours after injection for each dilution of cells
total viability/mortality calculations, described in Appendix A
only 4 mice were injected for this dilution o f cells
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Table 2.3. Summary o f 50% Lethal Dose Assay of Vibrio vulnificus Strains Using the
Iron-Mouse Method
Strain Tested

LD50

1003(0)

0.87 cells

1003 (T)

>6.5 x 107 cells3

Mutant #47

>2.4 x 107 cells3

Mutant #54

>2.55 x 107 cells3

greatest number of cells injected in a group of 5 mice
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Production of hyaluronidase, chondroitin sulfatase and elastase activity may be
nonessential for virulence since they were not expressed by 1003 (O), whose LD^ was 1
cell. The roles that collagenase, mucinase, hemolysin, lipase and DNase play in the
virulence of the organism has yet to be determined.
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CAPSULE SYNTHESIS IN VIBRIO VULNIFICUS
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INTRODUCTION
The expression of a polysaccharide capsule has been shown to be one o f the
virulence factors required for the survival o f V vulnificus in a host, without which the
organism is destroyed by the immune system. The presence of the capsule on the
exterior o f a cell results in an opaque (O) colony morphology on an agar surface, as
opposed to the nonencapsulated, strains, which appear translucent (T). The
nonencapsulated colony morphotypes arise randomly during routine bacteriological
manipulation of encapsulated strains, as explained in Chapter 1. Once nonencapsulated,
the incidence of reversion back to the encapsulated state is rarely observed, but has
been reported (Yoshida et al., 1985; Wright et al., 1990), indicating the loss of CPS
production can be reversible. This reversibility suggests that a deletion or
recombination event that results in a loss o f genetic material is not likely responsible for
the loss of capsule production. Instead, a regulatory element may be involved, which
has the ability to turn off capsule expression at times when it is not necessary for
survival of the organism, such as on the surface of an agar plate, and turn it on again in a
harsh environment, such as normal human serum. A mobilizable insertion sequence,
such as that o f Pseudomonas aeruginosa (Bartlett and Silverman, 1989), is also a
possibility, which may be capable o f inserting into capsule genes to cause the loss of
capsule production and then excise itself to restore capsule production. However, the
instance o f reversion is rare, with most translucent strains of V vulnificus unable to
regain the ability to produce a capsule, even in harsh environments, (Wright et al., 1990;
Simpson et al., 1987) suggesting a loss o f genetic material is indeed a possibility.
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Because so few researchers have reported reversion of the translucent strains, the
opaque to translucent pathway has been labeled unidirectional, and the occasional event
of reversion remains unexplained. Neither explanation of deletion nor regulatory
element fully explains the event that leads to the random loss of capsule expression, but
evidence for both exists to further complicate the issue.
Before the loss of capsule production can be explained, the capsule locus must
be located and defined to some extent. The capsule genes of wild-type, encapsulated
strains can be used to determine the events which lead to the loss of capsule production
in nonencapsulated strains. So to study the process of capsule synthesis, we began at
the genetic level to identify genes essential to capsule expression of Vibrio vulnificus.
Utilizing transposon mutagenesis, mutants were generated that no longer expressed a
discernible polysaccharide capsule, as described in Chapter 1. Southern blot analysis
allowed the transposon to be located in the genome of each mutant following
chromosomal digestions with various restriction enzymes. These fragments could be
used to sequence the flanking regions o f chromosomal DNA that most likely encode a
gene involved in capsule synthesis of V vulnificus. This approach has proven to be a
good starting point for the identification of the capsule gene locus of V vulnificus.
MATERIALS AND METHODS

Bacterial Strains and Plasmids. A summary of bacterial strains and plasmids is
shown on Table 3.1. Briefly, the encapsulated Vibrio vulnificus clinical strain 1003 (O)
was used for transposon mutagenesis, from which nonencapsulated transposon mutants
were obtained. The plasmid pBluescript SK- (Short et a l, 1988) and the mobilizable
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vector pBBRlMCS (Kovach et al., 1994) were used to clone V vulnificus
chromosomal DNA. Plasmid DNA was first introduced into E. coli DH5a MCR
(Grant et al., 1990) by electroporation for propagation of each vector. For
complementation assays where conjugation was to be used, pBBRlMCS that contained
inserts o f V. vulnificus chromosomal DNA was introduced into E. coli M CI061 cells
(Wertman et al., 1986) by electroporation. The conjugation event also required the
transfer-proficient (Tra+) helper plasmid pRK20l3 (Figurski and Helinski, 1979) to
provide the transfer genes, in trans, required to mobilize pBBRlMCS from E. coli to V
vulnificus, which was accomplished in a triparental mating. Ten strains o f V vulnificus,
(Table 3.2) each with a different capsular serotype, (Simonson et al., 1994) were
examined for the epimerase gene. Vibrio cholerae 0139 was used in Southern
hybridizations and was also examined for the epimerase gene.
Growth Conditions. All strains of V. vulnificus and E.coli were grown in Heart
Infusion (HI) broth (Difco, Detroit, MI) supplemented with 2% NaCl for 18 hours
(overnight) at 37°C with shaking at approximately 200 rpm, unless otherwise stated.
Colistin (118ug/ml), kanamycin (50ug/ml), ampicillin (50ug/ml), and chloramphenicol
(30ug/ml) were added to media used to select transformants that contained the
appropriate antibiotic resistant gene.
Genomic DNA Isolation. The protocol followed to isolated genomic DNA was
described in Chapter 1, but will be briefly mentioned here. Again, the method of Chan
and Goodwin (1995), was utilized but modified for nonencapsulated strains by omitting
the addition of cetyltrimethylammonium bromide (CTAB). Colonies were transferred
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Table 3.1. Bacterial Strains and Plasmids
Description

Reference

V vulnificus 1003 (O)

Encapsulated, clinical strain (Simonson and Siebeling, 1993)

Transposon mutants

Nonencapsulated, derived from
1003 (O), Kmr

Chapter 1

E coli DH5ccMCR

endAl hsdRl 7 (rkmk") supE44
thi-IrecAl gyrA (NaP) relAl
A(lacIZYA-argF) U169 deoR
($>$0dlacA(lacZ)MI5) el4
A{mcrC-mrr)

(Grant etal., 1990)

E coli MCI061

araD139 A(ara-leu)7696
galElS galKl6 A(lac)X74
rpsL (StrO hsdRl (rk'mk*)
mcrA mcrBI

Vibrio cholerae 0139

Encapsulated, clinical strain

pBluescript SK-

Apr

pBBRlMCS

mob*, Clr

pPCGl

Tn and Vibrio DNA of
Tn mutant #1 (2.3 kb) cloned
into pBluescript with Sacl

This study

pEpiBS

epimerase gene of 1003 (O)
(6.5 kb) cloned into
pBluescript with EcoRI

This study

pEpiBBR

insert from pEpiBS excised
by Xbal and HindlU and
cloned into pBBRlMCS

This study

pEpi2BBR

partial insert from pEpiBS
excised with Kpnl and
and cloned into pBBRlMCS

This study

pRK2013

RK2 transfer genes cloned
into a ColE 1 replicon, Kmr

(Wertman et al., 1986)

(Albert et al, 1993)
(Shorter al., 1988)
(Kovach et al., 1994)

(Figurski and Helinski, 1979)
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Table 3.2. Vibrio vulnificus strains that express CPS distinguishable by serological
methods
Strain

Capsular Serotype

Source

C7184

1

septicemia

1010

2

septicemia

1014

3

unknown

1007

4

septicemia

1657

5

wound

1866

6

septicemia

1002

7

septicemia

549

8

septicemia

938

9

eel isolate

1456

10

unknown

1003

9

wound
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from frozen stocks (at -85°C) to tubes containing 3 ml HI broth, supplemented with the
appropriate antibiotic. These cultures were incubated overnight at 37°C with rigorous
shaking, following which chromosomal DNA was extracted and stored at -20°C.
Plasmid DNA Isolation. All plasmid DNA was isolated using the Perfect Prep Plasmid
Extraction Kit (5 Prime 3 Prime, Inc.) according to the manufacturer’s instructions.
Briefly, a 3 ml culture of cells, grown overnight, was spun down in a single
microcentrifuge tube. Three solutions (provided) were simultaneously added to
sequentially resuspend the pellet, lyse the cells, and then neutralize the solution. Cell
debris was removed by centrifugation and the supernatant, containing the plasmid DNA,
was recovered and transferred to a spin column contained in a collection tube. The
plasmid DNA was bound by a DNA Binding Matrix and then purified by a wash with
Purification Solution (a buffered salt solution with 50% ethanol). Sterile water was
added to the column and all tubes were heated at 65°C to elute the plasmid DNA, which
was stored at -20°C.
Restriction Digestion and Agarose Gel Electrophoresis. For chromosomal digests, a
total of 30 ul DNA sample (from one DNA preparation) was used and 50 units o f the
appropriate restriction enzyme (NewEngland Biolabs Inc, Beverly, MA) was added with
10X buffer and 100X bovine serum albumin (BSA), if required. For digestion of
plasmid DNA, a 20 ul aliquot from a Perfect Prep plasmid prep was used, with 20 units
of restriction enzyme, 10X buffer, and 100X BSA, supplied by the manufacturer, if
required. Digests were incubated at 37°C overnight and then tubes were heated to 65°C
for 10 minutes to denature the enzyme. The appropriate amount of 6X loading buffer
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(0.25% bromophenol blue, 0.25% xylene cyanol, 40% sucrose in water) was added to
each tube and the entire contents were loaded into the wells of a 0.8% agarose gel for
chromosomal DNA and a 1% agarose gel for plasmid DNA. Gels were stained with
ethidium bromide and visualized using a UV lamp on the EagleEye II (Stratagene,
LaJoIla, CA).

DNA Cloning. The plasmid pPCGl contained a 2.3 kb insert that consisted of the
transposon insertion and flanking chromosomal DNA o f V vulnificus transposon mutant
1 that was cloned into the vector pBluescript (Table 3.1) and was constructed in the
following manner. To identify the gene disrupted by the transposon insertion,
chromosomal DNA o f one transposon mutant, specifically transposon (Tn) mutant #1,
was digested with Sacl (New England Biolabs) and ligated into similarly digested
pBluescript SK- DNA using a Fast-Link DNA Ligation and Screening Kit (Epicentre
Technologies, Madison, WI). The ligation mixture consisted of 1.5 ul of 10 mM ATP
(adenosine triphosphate), 1.5 ul 10X ligation buffer, 1 ul (2 units) Iigase, 100 ng of
pBluescript DNA, and 200 ng o f genomic DNA o f Tn mutant #1. The mixture was
incubated at room temperature (25°C) for five minutes, heated to 65°C for 15 minute*;
to denature the enzyme and increase the transformation efficiency, and then chilled on
ice. Two ul of the ligation mix was added to 40 ul o f E. coli DH5aMCR cells
previously made competent with five washings with 10% glycerol, which rid the cells of
ions that conduct electricity. After five minutes incubation on ice, E. coli DH5aMCR
cells were then transformed using the Gene Pulser (BioRad, Hercules, CA) at 2.5 kV,
200 Q and 25 uF. The cell mixture was then added to 3 ml HI broth and incubated at
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37°C with slight aeration for one hour. To Hl/kanamycin/ampicillin agar plates, 100 ul
aliquots of the cell suspension was added and the plates were incubated for up to five
days at 30°C. Plasmid DNA from kanamycin and ampicillin resistant transformants was
verified by Southern blotting with the kanamycin-probe described in Chapter 1 and was
designated pPCGl (putative capsule gene from Tn mutant #1).
The plasmid pEpiBS (Table 3.1) was constructed to further analyze the putative
sequence disrupted by the transposon, and the gene was cloned from the wild-type
encapsulated strain 1003 (0), from which Tn mutant #1 was derived. The genomic
DNA of V. vulnificus 1003(0) was isolated, digested with £coRI and electrophoresed
in a 0.8% agarose gel. The 6.5 kb fragment, recognized by epimerase-probe A (to be
discussed shortly), was excised from the gel and purified using the QlAquick Gel
extraction kit (Qiagen Inc., Chatsworth, CA), according to the manufacturer’s protocol.
The pBluescript DNA used was digested with EcoRI and treated with calf intestinal
alkaline phosphatase (Gibco BRL, Gaithersburg, MD). Following two extractions with
phenol/chloroform/isoamyl alcohol (25:24:1), the pBluescript DNA was ethanol
precipitated and resuspended in 20 ul sterile deionized H20 The ligation was
performed as described for pPCGl with 200 ng of 1003 (O) chromosomal DNA of
approximately 6.5 kb in size as the insert. The ligation mixture was incubated for five
minutes at room temperature and then heated to 65°C for 15 minutes to denature the
enzyme. To 40 ul of competent £. coli DH5aMCR cells, 2 ul of the ligation mix was
added and incubated for five minutes on ice. Electroporation, as described above, was
used to transform E.coli DH5aMCR cells following which were transferred to 3 ml HI
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broth and the cell suspension was incubated at 37°C for one hour with slight aeration.
Onto Hl/ampicillin plates, 100 ul aliquots were added and the plates were incubated at
37°C overnight. Colonies that contained the plasmid and gene of interest were
identified by colony blots (described below) and were designated pEpiBS.
The plasmid pEpiBBR was constructed for the complementation assay, and the
6.5 kb insert from pEpiBS was cloned into the mobilizable vector, pBBRlMCS to allow
the broad host range plasmid to be introduced into V vulnificus by conjugation.
Because the multiple cloning site (MCS) of pBBRlMCS does not contain an EcoRI
site, a double digest was required to remove the 6.5 kb insert from pEpiBS. The
enzymes Xbal and Hincfl.II were used because their sites were not present in the insert
DNA, excising the complete insert from the pBluescript vector. The ligation was
performed as outlined above, resulting in the vector pEpiBBR. Electroporation was
used to transform competent E. coli MCI061 cells which were then added to 3 ml HI
broth and incubated at 37°C for one hour with slight aeration. Onto Hl/chloramphenicol
plates, 100 ul aliquots o f the cells suspension were added and the plates incubated
overnight at 37°C. Resulting colonies were tested for the plasmid of interest using the
epimerase-probeA.
The plasmid pEpi2BBR (Table 3.1) was constructed similarly to that of
pEpiBBR, but Kpnl was the restriction enzyme used to digest and excise the epimerase
region from pEpiBS. The insert cloned into pBBRlMCS was 4.2 kb in size and
included the epimerase gene with an additional 200 bp o f upstream DNA. Following
ligation, the vector was electroporated into E. coli MCI061 and colonies resistant to
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chloramphenicol were examined for the presence o f pEpi2BBR with the epimeraseprobe A.
Probe Synthesis. Epimerase-Probe A: To detect the putative epimerase gene in V
vulnificus 1003 (O) and V cholerae 0139, a digoxygenin-Iabeled probe (epimeraseprobe A), specific for 139 bases of the region o f V vulnificus DNA disrupted by the
transposon, was prepared using the PCR DIG Synthesis Kit, as described in Chapter I.
The primers were designed using primer designer software and are 5'
ATAGTGTTGACCATCCGGTG 3' for the coding strand and 5'
GGACGCCCCCAAGAGCCATA 3' for the noncoding strand. Each 50 ul PCR mix
consisted of 2.5 mM MgCU, 10 ng pPCGl as template DNA, 5 mM of each primer, 1 ul
DMSO, 5 ul I OX buffer, 5 ul I OX dig-labeled nucleotide mix and 2.6 units DNA
polymerase (high fidelity). A total o f 30 cycles were completed on a Perkin Elmer Cetus
480 thermal cycler which consisted o f ten cycles at 95°C for 10 seconds, 60°C for 30
seconds and 72°C for 2 minutes and next, 20 cycles at 95°C for 10 seconds, 60°C for 30
seconds and 72°C for 2 minutes with a 20 second elongation starting at cycle 11.
Twenty ul of the PCR mix was electrophoresed on a 2% agarose gel to determine if
DNA fragment amplification had occurred.
Epimerase-Probe B: A second probe complimentary to the disrupted capsule
gene was synthesized (epimerase-probe B) and was specific for 83 bp internal to the 139
bp o f the region amplified by PCR. The probe was synthesized using the PCR DIG
Probe Synthesis Kit (Boehringer Mannheim). Primers used were
5'ACGAACTTATGGCTCATAGC3' for the coding strand and
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5'CCAAGAGCCATACACCGTAA3' for the noncoding strand. The PCR reaction mix
and thermal cycler parameters are the same as those described above. PCR products
were verified on a 2% agarose gel.
Colony Blots. Colony blots were used to locate the plasmids that contained inserts of
the epimerase gene. The protocol followed was that suggested in the Genius 3 Kit of
Boehringer Mannheim. Briefly, a nitrocellulose filter (Schleicher and Schuell) was
placed on top o f each plate for one minute and marked according to position on each
plate. The filters were placed colony side up onto a sheet o f 3M Whatman paper
saturated with denaturing solution 2 (0.5N sodium hydroxide, 1.5M sodium chloride,
0.1% sodium dodecyl sulfate) for 15 minutes, transferred to a second sheet of 3M paper
saturated with neutralization solution 2 (1M tris-hydrochloride, 1.5M sodium chloride,
pH 7.5) for 5 minutes and then to 3M paper saturated with 2X SSC (0.3 M sodium
chloride and 0.03M sodium citrate, pH 7) for 15 minutes. The filters were dried and
fixed at 120°C for 30 minutes and then incubated at 68°C for three hours in 3X wash
solution (3X SSC with 0.1% sodium dodecyl sulfate). To remove all cell debris, the
surface of each filter was wiped with a moistened towel. Once all visible cell debris
was removed, the filters were submerged in prehybridization solution (5X SSC, 0.1%
N-lauroylsarcosine, 0.2% sodium dodecyl sulfate, and 1% skim milk in 0.1 M maleic
acid and 0.15 M sodium chloride) for two hours at 60°C to prohibit the probe from
binding non-specifically to the filter. Next, the filter was submerged in hybridization
solution (prehybridization solution with 20 ng/ml o f the dig-labeled epimerase-probe A)
and was incubated at 60°C overnight to allow the probe to bind to its complimentary
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strand of DNA. After two wash steps to eliminate any unbound probe, the blot was
submerged in blocking solution (1% skim milk, 0.1 M maleic acid, 0.15 M sodium
chloride, pH 7.5) for 30 minutes at room temperature, as described in Chapter 1. Next
anti-digoxigenin/alkaline phosphatase was added and after a series of wash steps the
substrates nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-3-indole-phosphate
(BCIP) were added. A purple color is indicative o f a colony that contains the gene of
interest.
Nucleotide Sequencing. The plasmid pPCGl was sequenced in the following manner.
Upon the recovery o f pPCGl, the insert, consisting of the disrupted capsule gene of V
vulnificus along with the transposon, could now be sequenced using both the T3 and T7
primers of pBluescript (Short et al„ 1988). The CircumVent Sequencing Kit (New
England Biolabs, Inc.) was used according to the manufacturer’s instructions with
minor modifications. A sequencing mix was set up consisting of 1 pmol pPCGl as
template DNA, 10 pmol primer, 1.5 ul 10X Sequencing Buffer, 1 ul 30X Triton X-100
Solution, 1 ul (2 units) DNA polymerase and 2 ul (2 uCi) [a35S] dATP in a total volume
o f 15 ul. From this mix, 3.2 ul was added to each o f four tubes consisting of
deoxy/dideoxy nucleotide mixes, each containing a different dideoxy nucleotide
(adenine, guanine, thymine or cytosine). A drop o f sterile mineral oil was overlayed
onto each reaction. A Perkin Elmer Cetus 480 thermal cycler was used with the
parameters 95°C for 30 seconds, 55°C for 30 seconds, 72°C for 30 seconds for a total of
20 cycles.
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The plasmid vector pEpiBS contained an insert o f the putative gene of V.
vulnificus and was used as template for nucleotide sequencing with the ABI PRISM
Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer, Foster City, CA).
Again, both the T3 and T7 primers of pBIuescript were used to sequence the insert The
reaction mix consisted o f 1 pmol pEpiBS as template, 10 pmol primer, and 8 ul
sequencing mix (which contained the DNA polymerase, deoxynucleotides, and the four
dideoxynucleotides each labeled with individual dyes in a buffer solution) at a total
volume of 20 ul. The Perkin Elmer Cetus 480 thermal cycler was used with parameters
96°C for 30 seconds, 50°C for 15 seconds and 60°C for 4 minutes for 25 cycles.
Centrisep spin columns (Princeton Separations, Adelphia, NJ) were used to remove
primers and free nucleotides from PCR fragments, and the Perkin Elmer ABI 310
automated sequencer was utilized to sequence the template.
PCR Amplification. To determine the distribution of the V. vulnificus putative gene
among ten serologically diverse capsular types, a PCR amplification approach was used
for detection. The primers used to synthesize the epimerase-probe A (above) were used
to amplify the target region. A crude extract containing chromosomal DNA was
prepared from 1.5 ml broth cultures of each capsular serotype and used as template for
each amplification. Pelleted cells were washed once with 1 M NaCl, once with 0.5 M
NaCl, resuspended in 500 ul water and heated at 100°C for 15 minutes. Cell debris was
removed by centrifugation and the supernatant fluid, containing the chromosomal
DNA, was used as template. Ready-To-Go PCR Beads (Pharmacia Biotech Inc.,
Piscataway, NJ) were used, with the additions o f 2.5 ul DNA template, 1 ul of each 10
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uM primer solution and 20.5 ul sterile, deionized water to each tube. Amplification was
performed in a Perkin Elmer 480 Thermal Cycler, using the parameters suggested for
the Ready-To-Go PCR Beads (Pharmacia) with a modification of the annealing
temperature to 60°C. Parameters included one cycle at 95°C for five minutes, followed
by 35 cycles at 95°C for one minute, 60°C for one minute and 72°C for two minutes.
PCR products were electrophoresed on 8% nondenaturing polyacrylamide gels, stained
with ethidium bromide and visualized using the Eagle Eye II (Stratagene).

Southern Blotting. Using the epimerase-probe B, Southern blotting was employed to
ensure that the PCR products described above were indeed amplification o f a region of
the epimerase gene. The DNA fragments electrophoresed on 8% nondenaturing
polyacrylamide gels were electro-blotted onto charged nylon Zeta-Probe Blotting
Membranes (BioRad, Inc.) in 0.5X TBE buffer (50 mM boric acid, 50 mM Tris, ImM
ethylenediamine tetraacetic acid) at 80 V for one hour. The DNA was then denatured
and fixed onto the membrane in 0.4 M sodium hydroxide for ten minutes, rinsed with
2X SSC and air dried. The protocol outlined in Chapter 1 for Southern blotting and digdetection was then followed, with epimerase-probe B used to detect amplification o f the
epimerase gene.

Complementation. In order to complement the disrupted capsule gene o f Tn mutant
#1, the mobilizable vectors pEpiBBR and pEpi2BBR were constructed and first
introduced into an E. coli strain designated MCI061 (Wertman et al., 1986). Because
MCI061 does not possess the transfer (tra) genes which are necessary for conjugation, a
helper plasmid, pRK2013, was required. pRK2013 is a self-transmissable derivative of
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an RK2 plasmid that encodes for all o f the transfer genes necessary for successful
mobilization of a plasmid. By means o f a triparental mating, whereby 1 ml aliquots of
overnight cultures o f: 1) an E. coli strain containing pRK2013,2) E. coli MC1061
containing pEpiBBR or pEpi2BBR and 3) V. vulnificus Tn mutant #1 were mixed and
washed in HI broth. The resulting cell pellet was resuspended in 30 ul HI broth and
spotted onto a nitrocellulose filter placed on the surface o f an HI agar plate which was
incubated overnight at 30°C. The filter was added to 5 ml HI broth and vortexed to
remove all discernible cells. Onto Hl/chloramphenicol/colistin plates, 100 ul of the cell
suspension was added and plates were incubated overnight at 30°C, selecting for only V
vulnificus cells containing the pEpiBBR or pEpi2BBR vectors.
Com puter Analysis. All nucleotide sequences obtained were entered into the Basic
Localization Alignment Search Tool (BLAST) (Altschul et al., 1990) for comparison to
various similar nucleotide sequences. Translation from nucleotide sequence was
performed using the Clone Program (Science and Educational Software) and the
determined amino acid sequence was also entered into BLAST and matched with
proteins o f similar sequence. “Alignment” o f amino acid sequences to determine
regions o f similarity between two proteins was done using the Align Query (Myers and
Miller, 1988). Protein secondary structure was predicted using the SSP program
(Solovyev and Salamov, 1994).
RESULTS AND DISCUSSION
The capsule gene locus of V vulnificus has not been identified, to date, leaving
the gene arrangement to only be speculated upon with examples of well studied systems
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such as Escherichia coli, Haemophilus influenzae and Klebsiella pneumoniae as
possibilities. Capsule studies have, instead, focused on identification o f “capsule
types”, resulting in the identification o f at least 13 distinct serological CPS types
(Simonson et a l, 1994) and 15 CPS chemotypes o f V. vulnificus identified by highperformance anion-exchange chromatography (HPAEC) and nuclear magnetic
resonance spectroscopy (NMR) (Hayat et al., 1993). The evidence o f multiple capsule
types exemplifies the prospective complexity of the capsule gene arrangement, perhaps
similar to the 80 capsule types o f E. coli (Orskov and Orskov, 1992). The identification
of genes possessed by one strain o f V vulnificus was proposed as a starting point to
identify a capsule gene locus. The study o f these genes can eventually be utilized for
comparison to those in various encapsulated strains, identifying genes which are
“capsule-type-specific” and those which are common to all encapsulated strains of V.
vulnificus. In addition, any identified gene locus should be compared to similar genes
found in nonencapsulated strains, to define any events which might lead to the
spontaneous loss of capsule production. Our strategy for initially locating the capsule
genes of V. vulnificus was to disrupt a gene essential for capsule expression in V
vulnificus by transposon mutagenesis, clone that region o f chromosomal DNA, and then
to identify that gene through sequence analysis, whose presence can be determined in
strains of various capsule types using PCR amplification and Southern blotting.
To identify a gene disrupted by the transposon, the genomic region containing
the transposon and flanking chromosomal DNA of Tn mutant #1 was cloned into
pBluescript, resulting in pPCGl. Using the T7 primer, sequence analysis revealed 246
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bp of V. vulnificus chromosomal DNA before the transposon was located. Figure 3.1
shows the site of transposon insertion with the customary 9 bp repeats o f Vibrio
chromosomal DNA formed on either side o f the insertion sequences. The derived
nucleotide sequence o f the disrupted V vulnificus DNA was entered into BLAST and
found to be 76% identical to 246 bases of a nucleotide-sugar epimerase gene,
specifically orf 9 o f Vibrio cholerae 0139, which has been shown to be involved in the
capsule production of this organism (Comstock et a l, 1996).
Southern blot analysis, utilizing the dig-labeled epimerase-probe A, revealed the
size of the £coRI digested fragment from both V. vulnificus 1003 (O) and V cholerae
0139 that contained the epimerase gene (Figure 3.2). A 21 kb fragment of V cholerae
0139 was recognized by the probe. This fragment was cloned by Comstock et al.
(1996) and was shown to contain genes responsibie for capsule production of 0139,
including the nucleotide-sugar epimerase, that were not detected in O l strains of V.
cholerae (Comstock et al., 1996). A 6.5 kb fragment of V vulnificus 1003 (0) was also
recognized by the probe and was therefore assumed to contain the epimerase gene. This
fragment was extracted from an agarose gel and cloned into pBluescript, resulting in
pEpiBS. The insert was partially sequenced and the epimerase gene was found
immediately adjacent to the T3 region of pBluescript. Analysis of the nucleotide
sequence showed that an £coRI site was present at the 3' end of the gene, allowing only
992 bases o f the V vulnificus DNA to be cloned (Appendix B). The epimerase of V
vulnificus matched the V. cholerae 0139 nucleotide and amino acid (Figure 3.3)
sequences with 75% and 85% identity, respectively. The BLAST similarity
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5'
GACTTCACC
GACTTCACC............
[IS10R - kanamycinr gene - IS10R]
CTGAAGTGG
CTGAAGTGG............

652

660

652

660

5'

Figure 3.1. Site of transposon insertion into V. vulnificus chromosomal DNA
Nine base pair repeats o f V vulnificus chromosomal DNA were formed at the site of
insertion, flanking the right insertion sequences (IS10R) of the transposon. The repeats
are located in the 3' end o f the epimerase gene at bp 652 to 660.
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Figure 3.2. Southern blot o f V vulnificus 1003 (O) and V cholerae 0139 chromosomal
DNA hybridized with the epimerase probe A.
The epimerase gene was located on a 6.5 kb fragment o f V. vulnificus 1003 (O) (lane 1)
and a 21.5 kb fragment o f V cholerae 0139 (lane 2) when digested with the restriction
enzyme ZTcoRI.
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search has also shown the epimerase o f V. vulnificus to be highly similar to epimerases
of several organisms in addition to V. cholerae 0139. Those exhibiting the greatest
identity to the putative epimerase o f V. vulnificus are identified on Table 3.3 and are
briefly described. The orf 2 of E. coli 0111 has been described by Bastin et al. (1993)
and has been found to be homologous to epimerases o f various organisms. This
organism produces an O-antigen capsule so-called because the sugar composition of the
O-antigen lipopolysaccharide (LPS) side chain and the capsule are identical (Goldman
et al., 1982). The CapI of S. aureus M is part of a capsule gene locus. It has been
described by Lin et al. (1994) as the NAD-dependent enzyme involved in the synthesis
of N-acetylgalactosamino uronic acid due to its high homology to the VipB protein of
Salmonella typhi whose Vi polysaccharide is a homopolymer of N-acetylgalactosamino
uronic acid. It has also been shown to have high homology with various epimerases.
The putative glucose epimerase of B. thuringiensis was identified by Dunn et al. as part
of a virulence locus consisting of PK1 and cap genes.
Each o f the epimerases identified possesses one common feature, the
dependence upon NAD as a cofactor for the formation of a ketose intermediate during
enzymatic function (Frey, 1987). Wierenga et a/.(1986) has defined an amino acid
“fingerprint” in addition to a pap fold that identifies the NAD binding domain of a
protein. The epimerase of V. vulnificus, described in this study, contains the consensus
amino acid sequence and the PaP fold (Table 3.4), as defined by computer analysis
(Solovyev and Salamov, 1994), in its N-terminus required for NAD binding. The Cterminus domain of the epimerase is responsible for binding to the substrate (Thoden et
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Figure 3.3. Alignment of amino acid sequences of the putative nucleotide-sugar epimerases of V vulnificus 1003 (O) and V cholerae
0139.
V. vulnificus 1003 (O) (top) matches the sequence of the nucleotide-sugar epimerase of V. cholerae 0139 (bottom) with 85 % identity.
Exact matches (:) and conservative substitutions (.) are shown.
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Table 3.3. A comparison of the amino acid sequences found highly similar to the
putative epimerase o f V vulnificus determined by the Basic Local Alignment Search
Tool (BLAST)
Organism

Homologous
protein

Amino Acid
Identity (%)*

Smallest Sum
Probability (P)

V cholerae 0139

NT-sugar epimerase

85

1.3 x I O'199

E. coli 0111

orf 2 (hypothetical protein)

63.5

8.5 x 10-149

S. aureus M

Cap I

56

1.5 x I O'128

B. thuringiensis

glucose epimerase

53.7

1.4 x lO*"9

a Based on individual comparisons with putative epimerase of V vulnificus
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al., 1996) with the nucleotide portion serving as the binding anchor (Frey, 1996). While
various amino acid sequences have been suggested to be involved in substrate binding
(Thoden et a l, 1996), a consensus sequence has not been identified for substrate
specificity.
The epimerase gene was shown to be present in strain 1003 (O), but its
dissemination amongst additional encapsulated strains of V vulnificus remained to be
determined. PCR was used to demonstrate the presence o f the epimerase gene in the
genome of the ten V. vulnificus strains listed on Table 3.2, each with a distinct CPS
serotype. As shown in Figure 3.4, all o f the ten V vulnificus capsular serotypes and V.
vulnificus 1003 (O) show amplification of the 139 bp target region and were hybridized
by epimerase-probe B that is specific for 83 bp o f the epimerase gene. Collectively,
PCR amplification coupled with Southern blot analysis verified the presence of an
epimerase gene in the chromosome o f each strain.
Insertion of the transposon into the epimerase gene o f V vulnificus resulted in a
mutant which could no longer express a polysaccharide capsule, implying that this gene
was essential for capsule production. To ensure that the loss o f capsule production was
due to the disruption of the epimerase gene and not an effect on downstream genes, a
complementation assay was attempted. Upon cloning of the epimerase gene into the
mobilizable vector pBBRlMCS, the resulting vectors pEpiBBR and pEpi2BBR could
be used to provide the epimerase gene in trans and complement the mutation, perhaps
resulting in the production o f a polysaccharide capsule. Following several triparental
matings, the pEpiBBR vector was successfully introduced into V vulnificus transposon
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Table 3.4. The aligned NAD binding domain showing the “fingerprint” region and (tap
fold in the N-terminus o f putative epimerases

P

a

P

1003

K Y L V T G A A G F I G S A T A E K L N A A G H E V V G I D

0139

K Y L V T G A A G F I G S A T V K K L T E Q G H H V V G I D

0111

K Y L V T G A A G F I G F H V S K R L L E A G H Q V V G I D

Sa M

K I L

Bt

K I

I

T G T A G F I G S

L V T

H L A K K L

I

KQG

G A A G F I G F H L T K R L L A Q N

H Y V I

G V D

F H V I

G V D

The amino acid sequences shown are: Vibrio vulnificus 1003, residues 2-31; Vibrio
cholerae 0139, residues 2-31; Escherichia coli 0111, residues 2-31; Staphylococcus
aureus M, residues 2-31; and Bacillus thuringiensis, residues 5-34.
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5
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Figure 3.4. Detection o f the epimerase gene of V. vulnificus 1003 (O) in ten strains of V.
vulnificus, each expressing a distinct capsular type.
As shown in part A, PCR amplification resulted in a product of a 139 bp region o f the
putative epimerase gene in all V vulnificus strains tested. Part B shows the Southern
blot following hybridization of amplified products with epimerase probe B. Both
figures show V vulnificus strains: C7184 (lane 1); 1010 (lane 2); 1014 (lane 3); 1007
(lane 4); 1657 (lane 5); 1866 (lane 6); 1002 (lane 7); 549 (lane 8); 938 (lane 9); 1456
(lane 10); 1003 (lane 11).
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mutant 1, and resulted in complementation o f the disrupted epimerase gene (Figure 3.6),
which restored capsule production. This suggested that the presence of the epimerase
gene, in trans, allowed the once-nonencapsulated mutant to express a polysaccharide
capsule, which indicated that the epimerase gene was indeed essential for capsule
production and its disruption did not result in a polar effect on downstream genes.
However, the vector pEpi2BBR, which carried the epimerase gene and a smaller region
of upstream DNA, was successfully transferred to V vulnificus transposon mutant 1 but
could not reestablish capsule production. This may indicate the necessity o f a larger
promoter or enhancer region o f upstream DNA that is required for successful
transcription of the gene.
In addition to the putative epimerase gene identified in this study, additional
sequence analysis of pEpiBS, using the T7 primer of pBluescript, revealed a 250 bp
region of DNA 96% identical to the rfbQRS region of V cholerae 0139 (Figure 3.5),
which has been reported as an insertion sequence believed to be involved in DNA
rearrangement (Bik 1995). Insertion sequences, similar to the one mentioned here, that
are linked to genes involved in polysaccharide synthesis are not unusual in Vibrio
species (Stroeher 1997), suggesting its position relative to the epimerase may indicate
the presence o f other neighboring genes involved in CPS or even LPS production. But
because the epimerase and rfbQRS are separated by approximately 5kb, as determined
by agarose gel electrophoresis, these two genes may not be necessarily labeled as
“linked” until the adjoining DNA is identified as part of a capsule locus.
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1 GAATTCCTTCTGCGGATACGCTGTCTCGTGTGATGGGTATGATTAATCCTGTAGCTTTGC 6 0
iIII II
i t 1
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i 1
i 1
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i II
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i 1
i 1
i 1
i 1
I 1
i 1
i 1
i 1
t II
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i 1
i 1
i 1
i i1 1
i 1
i 1
i i1 1
i 1
i 1
i 1
i 1
i 1
i 1
i i1 i1 1
i i1 i1 1
i i1 1
i 1
i
3 7 6 GAATTCCTTCTGCGGATACGCTGTCTCGCGTGATGGGTATGATTAATCCTGTCGCTTTGC 4 3 5
61 AAAGAAGTTTCATTGCCTGGATGAAGGACTGCCATACACTGACGGATGGTGAAGTTATTG 1 2 0
1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
4 3 6 AAAGAAGCTTCATTGCCTGGATGAAGAACTGCCATACACTGACGGATGGTGAAGTGATTG 4 9 5
1 2 1 CCATCGACGGTAAAACATTACGCGGCTCTTATGACCGCTCGAAAGGCAAAGGAACGATCC 1 8 0
1 1 1 1 I 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I 1 II 1 1 1 1 1 1 1 1 1 1
4 9 6 CCATCGACGGTAAAACATTACGCGGCTCTTACGACCGCTCGAAAGGCAAAGGAACGATCC 5 5 5
1 8 1 ATATGGTGAACGCTTTTGCTACAGCAAATGGAATGAGCATTGGGCAACAGAATGTTGATT 2 4 0
1i 1i 1i 1i 1i 1i 1i 1i 1i i1 i1 i1 i1 1i 1i 1i i1 i1 1i 1i 1i i1 1i i1 1i i1 i1 1i 1i 1i i1 1i 1i 1i 1i 1i i1 1i i1 1i i1 1i i1 1i 1i i1 1i i1 Ii Ii Ii
1i i1 i1 i1 1i i1 i1
5 5 6 ATATGGTGAACGCTTTTGCTACAGCAAATGGAATGAGCATTGGGCAACTGAAGGTTGATT 6 1 5
2 4 1 CTAAGAGTAACGA 2 5 3
1111111111111
6 1 6 CTAAGAGTAACGA 6 2 8

Figure 3.5. Nucleotide sequence alignment o f a region of Vibrio vulnificus 1003
chromosomal DNA and the Vibrio cholerae 0139 rfbQRS locus.
The V. vulnificus nucleotide sequence (bases 1-253) located approximately 5 kb
upstream of the epimerase gene was found to be similar to the rfbQRS locus o f V.
cholerae 0139 (bases 376-628). The two sequences are 96% homologous, as
determined by BLAST.
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Figure 3.6. Comparison of colony morphology o f the nonencapsulated transposon
mutant I and the mutant following complementation with the epimerase gene in trans.
As shown in figure A, the nonencapsulated transposon mutant 1 appears translucent,
indicating the inability to produce a polysaccharide capsule. Figure B shows the
restoration of capsule production of the mutant following introduction of the pEpiBBR
vector, which supplies the epimerase gene in trans.
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In summary, transposon mutagenesis o f V vulnificus 1003 (O) has resulted in
the loss of CPS production and allowed the identification of an epimerase gene which is
essential for the synthesis o f a polysaccharide capsule. Specifically, epimerases mediate
for the interconversion of epimers, such as glucose and galactose, which differ in
configuration at a single asymmetric center. Epimerisation of activated
monosaccharides generally occurs in the early stages, or precursor synthesis, o f capsule
formation (Sutherland, 1990). As shown in this study, the disruption of a functional
epimerase results in the loss o f capsule production, implying that the conversion of
monosaccharides (precursors) is necessary for formation of CPS. Because the putative
nucleotide epimerase of 1003 (O) was present in various strains o f V. vulnificus, it most
likely provides an essential element which leads to CPS synthesis regardless of capsule
type.
The rfbQRS region found upstream of the epimerase gene in pEpiBS, shown to
be linked to polysaccharide synthesis genes in other Vibrios, implies that the capsule
gene locus of V vulnificus 1003 (O) has been located. This insertion-like sequence also
helps to further characterize the capsule synthesis of V vulnificus by proving additional
similarity to capsule genes of V cholerae 0139 and also V cholerae non-Ols. In
addition, the possible role of the rfbQRS in DNA rearrangement suggests that the
association o f this element with polysaccharide genes may not be accidental. The
conversion of encapsulated to nonencapsulated and the occasional reversion may due to
random “genetic disruptions” caused by this insertion sequence.

The instance of

reversion has also been noted for Pseudomonas atlantica (Bartlett and Silverman,
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1989) and Neisseria meningitidis (Hilse et al., 1996), where an insertion-like sequence
has been shown to “jump” around the chromosome, disrupting capsule genes, and then
excise itself, restoring capsule production. The rfbQRS may behave similarly, causing
the interconversion o f encapsulated and nonencapsulated strains o f V. vulnificus.
Further analysis o f the capsule gene locus of V. vulnificus is imperative, but this
study has shown to be a worthwhile endeavor o f identification o f capsule genes and
location of the capsule gene locus.
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SUMMARY
To begin the study of the capsule gene locus of Vibrio vulnificus, transposon
mutagenesis was utilized to identify genes essential to capsule synthesis, where
disruption resulted in a nonencapsulated phenotype. These transposon mutants were
grouped according to the genomic region o f insertion, suggesting that collectively, o f 23
mutants obtained, seven distinct chromosomal regions were disrupted which are
believed to be essential for expression o f a polysaccharide capsule. One mutant in
particular was chosen and the capsule gene disrupted by the transposon was identified as
a putative nucleotide-sugar epimerase. This epimerase was shown to be very similar to
the gene product of the orf9 o fV cholerae 0139, described by Comstock et al., (1996)
which has been shown to be involved in the capsule expression of this organism and
described as a nucleotide-sugar epimerase. Both nucleotide and amino acid sequence
analysis have shown that the putative epimerase described in this study is similar to
various epimerases from a wide range o f organisms. The pap-fold and “fingerprint”
consensus sequence in the N-terminus o f the epimerase shows it to have characteristics
common to NAD binding proteins, including epimerases. Although its role in capsule
production has not been established, the epimerase described within is believed to be
involved in precursor synthesis, most likely providing a common constituent or
“building block” required for capsule synthesis o f V vulnificus, despite differences in
capsule serotype. The epimerase gene is also believed to be proximate to additional
genes involved in polysaccharide synthesis because o f its position relative to the
r/bORS found upstream, which implies that a capsule gene locus of V vulnificus has
86
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been located. In addition, the rfbQRS locus may be involved in DNA rearrangement,
suggesting that its position relative to the polysaccharide genes may result in a
regulatory mechanism capable of turning capsule production on and off, such as in the
interconversion of encapsulated and nonencapsulated strains.
The fact that V. vulnificus clinical and environmental strains have been shown to
express immunologically distinct capsule serotypes, implies that genomic diversity
among strains is probable. However, the conservative nature of additional known
systems, such as E. coli and H. influenzae, propose the possibility of various
encapsulated strains o f V vulnificus possessing both conserved genes and diverse
“capsule type specific” genes in the capsule gene locus. If this is indeed the case, then
genes specific to capsule type may be utilized for detection as are serological reagents,
capable of differentiating between strains. This, however, remains to be determined and
must be addressed in future studies.
Concerning virulence, this study, as exemplified in Chapter 2, has shown that
expression of the polysaccharide capsule is essential for virulence of V vulnificus.
Despite expression o f numerous secondary virulence factors, the inability to express the
CPS resulted in avirulence for the translucent strains tested using the LD50 virulence
assay. In addition, secondary virulence factors, such as hyaluronidase, chondroitin
sulfatase and elastase, have been shown to be nonessential for virulence o f pathogenic
V vulnificus 1003 (O) whose LDS0 was determined as 1 cell in the absence o f these
three exoenzymes. The reason for the decreased expression o f some exoenzymes by the
wild-type nonencapsulated 1003 (T) is not known, but is not considered relevant due to

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

88
the fact that various other wild-type nonencapsulated strains did not lose their ability to
express these exoenzymes.
Overall, the role o f exoenzymes in virulence remains, as named, secondary to
that of the polysaccharide capsule, which allows the organism to survive the hostile
environment of the host. However, the 50% minimal lethal dose assay should not be
used to determine the absolute roles o f these exoenzymes in the virulence o f the
organism. Following intraperitoneal injections, the organism is administered directly
into the bloodstream of the host, mimicking a primary septicemia where the ability of
the organism to spread from its usual portal o f entry is dismissed. This study can only
claim that these exoenzymes have little to do with the virulence of the organism once a
septicemic state has been established. The role of these exoenymes play in invasion o f
the organism has not been addressed here and should not be disregarded.
In conclusion, this study has proven to be useful as a preliminary understanding
of capsule expression of V. vulnificus. The identification of a nucleotide-sugar
epimerase and its presence in various strains o f V. vulnificus suggests that it is a gene
involved in the synthesis o f CPS conserved amongst strains expressing distinct CPS
serotypes. Also, the capsule has been shown to act as a primary virulence factor once a
septicemic state has been established. Following injection into the peritoneal cavity o f
a mouse, the absence of a polysaccharide capsule results in an avirulent strain,
regardiess of the expression o f secondary virulence factors.
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APPENDIX A
EXAMPLE CALCULATION FOR DETERMINATION OF THE 50% LETHAL DOSE
OF A BACTERIAL STRAIN
I
H
HI
IV
V
VI
Total
Percent
Mortality
Strain Tested Dilution Cells / 0.5 ml Alive Dead
Alive Dead
1.25 x10s
0
10'2
5
0
23
1003(O)
100
io-4

1.25 xlO 3

0

5

0

18

100

10'5

1.25 xlO 2

0

5

0

13

100

io-6

1.25x10*

I

4

I

8

89

IO'7

1.25x10°

2

3

3

4

57

10'*

1.25 xlO'*

3

1

6

1

14

The above table is similar to the one used by Reed and Muench who first
described the method of calculating the LDS0 o f a microorganism (Reed, 1938). The
Roman numerals above each column will be used to explain the formulation.
i] Values from column IV Alive are transferred to column V Alive by adding numbers
o f alive mice from each dilution downward. Example: Dilution I O'6 had only 1 mouse
alive after 48 hours. This 1 is transferred to column V Alive for IO'6. The 10'7 dilution
(column IV) has 2 alive mice. This 2 is added to the I mouse from 10"6 o f column V
Alive to result in the 3 in column V for the 1O'7dilution. Next, the 3 alive for 10'*
(column IV Alive) dilution is added to the 3 of 10'7 dilution (column V Alive) to give 6
total live mice in column V for the 10 *dilution. The deaths for column V are figured in
the same manner, but moving in an upward direction.
ii] Column VI, or percent mortality, for each dilution is calculated by dividing the
number of deaths in column V by the total o f Alive + Dead also in column V. For
example: The 10'7dilution resulted in 57% mortality. This was calculated by adding 3
alive +4 dead to total 7. The number dead (4) is then divided by the total (7) to give
percent mortality (57%).
iii] Column VI must be observed to find the percent mortalities immediately above and
below 50% mortality. The percentage above is designated A and percentage below is B,
to obtain a value for C.
Example: A = 57, B = 14
Formula: C = A - B
Example: C = 57 - 14
C = 43
(appendix con’d.)
100
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iv] A value for D must be obtained.
Formula: D = 50 - (lowest value o f A and B)
v] Both C and D are now used to determine X.
Formula: X = D ^ C

Example: D = 50 - 14
D = 36
Example:
X = 0.84

X = 36 -*•43

vi] A value for Y must be obtained using the number o f cells / ml that resulted in the
percent mortalities of both A and B. Note: Above values in column ID are given for 0.5
ml aliquots, so these must be multiplied by 2.
Formula: Y = log (number of cells for A) - log (number of cells for B)
Example: Y = log (2.5 x 10°) - log (2.5 x 10'1)
Y = log 2 .5 - log 0.25)
Y = (0.4) - (-0.6)

Y= 1
vii] Now that both X and Y are defined,they can be used to determine Z.
Formula: Z = (X) (Y)
Example:Z = (0.84)(1)
Z = 0.84
viii] Finally, all values necessary to determine the LDS0 have been defined.
Formula: log LDS0 = Z + log (number of cells for B)
Example: log LDS0 = 0.84 + (-0.6)
log LDj0 = 0.24
Formula: LD50 = anti-log 0.24
LDS0= 1.74
Note: This value if for cells / ml. Only 0.5 ml was
injected into mice in this study!
LDS0 = 1.74 -5- 2
LDjo = 0.87
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APPENDIX B
THE DERIVED NUCLEOTIDE SEQUENCE OF THE PUTATIVE EPIMERASE
GENE OF VIBRIO VULNIFICUS
1

ATGAAATACT TAGTAACTGG TGCTGCTGGT TTTATTGGCA GTGCGACGGC AGAGAAACTT
TACTTTATGA ATCATTGACC ACGACGACCA AAATAACCGT CACGCTGCCG TCTCTTTGAA

61

AATGCTGCAG GGCATGAAGT TGTGGGCATC GATAATCTAA ATGATTACTA CGATGTGAAT
TTACGACGTC CCGTACTTCA ACACCCGTAG CTATTAGATT TACTAATGAT GCTACACTTA

121

TTAAAACATG CGCGGCTTGC TCGTATTGAA AATCCACTGT TCAAATTTGT AAGCGTAGAT
AATTTTGTAC GCGCCGAACG AGCATAACTT TTAGGTGACA AGTTTAAACA TTCGCATCTA

181

ATTTCAGATC GTGGAGCGAT GGAGCAGTTG TTTGCCACCG AGAAGTTTGA TCGTGTGATC
TAAAGTCTAG CACCTCGCTA CCTCGTCAAC AAACGGTGGC TCTTCAAACT AGCACACTAG

241

CACTTGGCTG CCCAAGCTGG TGTACGTTAT TCACTAGAAA ACCCACATGC TTATGCGGAT
GTGAACCGAC GGGTTCGACC ACATGCAATA AGTGATCTTT TGGGTGTACG AATACGCCTA

301

TCAAATTTGG TTGGACATCT CAATATTCTT GAGGGCTGTC GTCAAAACAA AGTAAGCCAT
AGTTTAAACC AACCTGTAGA GTTATAAGAA CTCCCGACAG CAGTTTTGTT TCATTCGGTA

361

CTAGTATATG CATCTTCGAG CTCTGTATAT GGACTAAATG CAAAAGTGCC CTTTTCAACT
GATCATATAC GTAGAAGCTC GAGACATATA CCTGATTTAC GTTTTCACGG GAAAAGTTGA

421

TCGGATAGTG TTGACCATCC GGTGTCGCTT TATGCTCCAA CCAAGAAGTC TAACGAACTT
AGCCTATCAC AACTGGTAGG CCACAGCGAA ATACGAGGTT GGTTCTTCAG ATTGCTTGAA

481

ATGGCTCATA GCTATTCCCA TCTTTACGAC ATTCCAACAA CGGGGTTACG CTTTTTTACG
TACCGAGTAT CGATAAGGGT AGAAATGCTG TAAGGTTGTT GCCCCAATGC GAAAAAATGC

541

GTGTATGGCT CTTGGGGGCG TCCGGACATG GCCCCATTTA TTTTCACTAA GAAAATTCTT
CACATACCGA GAACCCCCGC AGGCCTGTAC CGGGGTAAAT AAAAGTGATT CTTTTAAGAA

601

GATGGTGATG CAATTGATAT CAACAACAAT GGTGATATGT GGAGAGACTT CACCCATGTA
CTACCACTAC GTTAACTATA GTTGTTGTTA CCACTATACA CCTCTCTGAA GTGGGTACAT

661

GATGATATTG TTGAAGGTGT AGTTCGCATT GCTGATGTCA TCCCAACCCG AAATGAATCT
CTACTATAAC AACTTCCACA TCAAGCGTAA CGACTACAGT AGGGTTGGGC TTTACTTAGA

721

TGGACTGTTG AAGCAGGGAC ACCAGCAACG AGCTCTGCGC CATACTCGGT TTATAACATT
ACCTGACAAC TTCGTCCCTG TGGTCGTTGC TCGAGACGCG GTATGAGCCA AATATTGTAA

781

GGTCATGGTT CTCCTATCAA TCTGATGGAT TTTGTGAAAG CAATTGAAAA TGAACTTGGT
CCAGTACCAA GAGGATAGTT AGACTACCTA AAACACTTTC GTTAACTTTT ACTTGAACCA

841

ATTGAAGCGA AGAAAAACTT CCGCGAAATG CAGCCTGGGG ATGTTTATCA AACTTATGCT
TAACTTCGCT TCTTTTTGAA GGCGCTTTAC GTCGGACCCC TACAAATAGT TTGAATACGA

901

GATACAGAAG ATTTGTTTAC CGCTACTGGT TACAAACCAA GAGTAACAGT TAAAGAAGGC
CTATGTCTTC TAAACAAATG GCGATGACCA ATGTTTGGTT CTCATTGTCA ATTTCTTCCG

961

GTTGCAGAGT TTGTTTCTTG GTATAAAGAA TT
CAACGTCTCA AACAAAGAAC CATATTTCTT AA
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